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ABSTRACT 
The development of a wide spectrum of new strategies based on controlled drug delivery 
systems for tumor treatment have attracted a great deal of interest thanks to their ability to 
encapsulate and control the release of a large array of anticancer drugs and to their 
targeting ability to many tumor sites. In the last years, the use of polysaccharides for the 
development of innovative formulations for drug delivery and targeting is rapidly growing. 
This could be probably attributed to their peculiar properties, such as biodegradability, 
biocompatibility, large availability as natural source, low cost manufacturing process and 
to the presence of multiple reactive groups in their structures, which make them suitable 
for an easy chemical functionalization. In this context, the overall aim of this thesis was to 
design, produce and characterize innovative formulations based on polysaccharides with 
potential application in tumors treatment. In particular, in the present thesis, two different 
strategies were envisaged.  
The first one is based on the evidence that chemoattraction through the CXCR4-CXCL12 
axis has been shown to be an important mechanism to direct circulating tumor cells toward 
distant sites. Thus, a fake metastatic niche made up of a gel loaded with CXCL12 was 
realized. This gel was engineered to create a steep concentration gradient of the chemokine 
in the proximity of the site of administration/injection thus diverting and capturing the 
circulating CXCR4
+
 tumor cells. To this aim, different thermo-responsive gels based on 
methylcellulose or poloxamers, with or without the polysaccharide hyaluronic acid, were 
designed, loaded with CXCL12 and their mechanical properties correlated with the ability 
to attract and capture in vitro CXCR4
+
 cells. 
The second strategy concerned the use of polysaccharides both as structural and coating 
component for different types of nano-carriers, prepared with simple and easily up-scalable 
manufacturing process. In this context, two different polysaccharides were investigated, 
hyaluronic acid and enoxaparin. These polysaccharides, thanks to their ability to recognize 
and bind specific receptors and growth factors overexpressed in tumor cells, can favor a 
greater drug accumulation to target sites, thus promoting and improving the selectivity and 
effectiveness of the chemotherapy. The nano-carriers here investigated are chitosan-based 
polyelectrolyte complexes, poly (lactic-co-glycolic acid) polymeric nanoparticles and self-
emulsifying drug delivery systems. 
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CHAPTER 1 
General introduction 
 
1.1 Polysaccharides 
Polysaccharides are a family of natural polymeric carbohydrate molecules, derived from 
plant, animal or algal sources in which repeated chains of monosaccharide or 
oligosaccharide units are linked together through glycosidic bonds. Thanks to some 
characteristics of their chemical and biochemical composition, there are a large number of 
polysaccharides with different properties and structures [Liu et al., 2008]. The first 
classification is based on the type of monosaccharide components in the structure; if there 
is only one type of monosaccharide units, it can be defined homopolysaccharide whereas, 
if the polysaccharide is composed of two or more different monosaccharides, it is called 
heteropolysaccharide [Miller et al., 2014; Posocco et al., 2015]. Depending on their 
function, they can be classified as storage polysaccharides, an energetic glucose supply for 
the metabolism of vegetables and animals (e.g. glycogen), structural polysaccharides 
composing the vegetable tissue structures (e.g. cellulose) and specialized polysaccharides, 
with physical chemical properties suitable for their adhesion to contact-microenvironments 
(e.g. heparin sulfate). Moreover, for the presence/absence of superficial charge, they can be 
divided into non-polyelectrolyte polysaccharides (neutral charge), positively and 
negatively charged polyelectrolytes. Despite they are available as natural source, the 
presence of multiple reactive groups in their structures make them suitable for an easy 
chemical and biochemical modification, resulting in many types of polysaccharide 
derivatives [Bedini et al., 2017; Pawar et al., 2015]. Table 1.1 summarizes the chemical 
structure, source, charge and monosaccharide units composition of some of the most 
common polysaccharides. 
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 Structure Source Charge 
Monosaccharide 
units 
Chitosan 
 
 
Animal + 
 D-glucosamine 
 N-acetyl-D-  
glucosamine 
Dextran 
 
Microbial +  Glucose 
Alginate 
 
Algal - 
 β-D-
mannuronate 
 α-L-
guluronate 
    
Pectin 
 
Plant - 
 D-galacturonic 
acid 
 
Hyaluronic 
acid 
 
Human - 
 D-glucuronic 
acid 
 N-acetyl-D-    
glucosamine 
Table 1.1: chemical structure, source, charge and monosaccharide units of some polysaccharides 
 
1.2 Polysaccharide based formulations in drug delivery  
Polysaccharide based formulations for controlled drug delivery and targeting have been 
examined over the years as strategies to make chemotherapeutic treatments more effective 
and selective. Indeed, in contrast to conventional- dosage forms, they are able to control 
the delivery of loaded drug(s) and/or promote its (their) delivery to a specific target. By 
this way, it is possible to enhance the bioavailability of the active molecule(s), thus 
decreasing the administration dose, improving the patient’s compliance (thus resulting in 
decrease of the number administration and cost of the therapy) and minimizing the adverse 
side effects [Aziz, 1996; Mohanraj and Chen, 2006]. During the past decade, thanks to 
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their advantageous and peculiar properties, the use of polysaccharides for the development 
of drug delivery systems is rapidly growing [Laurienzo et al., 2015; Harshal et al., 2015]. 
It could be probably attributed to their large availability as natural source, low-cost 
manufacturing process, their biocompatibility and biodegradability; as other biological 
polymers, after administration, polysaccharides tend to be internalized into the cells, 
degraded and eliminated rapidly from the body, making their use safe and non-toxic. 
Moreover, thanks to the presence of several hydrophilic moieties in their structures, they 
are able to form covalent bonds with biological/mucous membrane, enhancing their 
mucoadhesion and bioadhesion. By this way, they can be used to extend the bioavailability 
and the release at specific cells or organs of the drug loaded into formulations. These 
attractive properties allowed the use of polysaccharides in several biomedical applications 
such as ophthalmic, infectious diseases, diabetes therapy, diagnostics and cancer 
[Camponeschi et al., 2015; Lemarchand et al., 2005; Lemarchand et al., 2006; Maltese et 
al., 2006]. In particular, in drug delivery applications, polysaccharides represent attractive 
candidates both as structural components of drug delivery formulations and/or as coating 
materials to obtain carriers endowed with hydrophilic surface with targeting ability 
[Kyung-Oh and Yoon, 2012; Ladaviere et al., 2007; Lemarchand et al., 2004]. Relying on 
their mechanism of action and method of administration, current available systems can be 
divided into two groups [Wolinsky et al., 2012]. The first one includes depot-forming 
formulations such as films, microparticles and gels. These systems are intended for local 
administration; by this way they can be directly implanted intra-tumorally or close to the 
target tumor tissue. The second group comprises nano-carrier based formulations, such as 
polyelectrolyte complexes (PECs), nanoparticles (NPs), and self-emulsifying drug delivery 
systems (SEDDS); they, thanks to their small size, are predominantly intended for 
intravenous injection.  
 
1.3 Clinical need for drug delivery systems in cancer therapy 
Despite a notable progress in cancer research, tumor remains one of the main causes of 
death worldwide [Ferlay et al., 2010; Bray et al., 2012]. The term tumor defines a group of 
diseases in which the growth of an abnormal mass exceeds that of a normal tissue and it 
progresses after cessation of the stimuli that have evoked it. In general, the size of organs is 
normally preserved within optimal values thanks to the action of control tools that regulate 
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the mitotic cells activity. New cells are produced to restore the oldest and/or damaged ones 
or to perform new functions. When these complex control mechanisms are altered and the 
balance between the cell growth and death is disturbed, a tumor may form. Cancer cells are 
able to reproduce continuously and they have no relation with the specific functions of the 
tissue with normal growth, from which they originate [Byrne et al., 2008; De Jong and 
Borm, 2008; Alexis et al., 2008]. Whereas the growth of some tumors remains limited to 
the originated organ (benign tumor), some of them loose contact inhibition, extracellular 
matrix (ECM) adhesion and penetrate into the bloodstream and/or lymphatic system 
[Hanahan and Weinberg, 2011]. By this way, they are able to migrate in other organs and 
tissues where, if it is present a favorable environment for their colonization and 
proliferation, a second tumor (or metastasis) may form [Arvelo et al., 2016]. In the latter 
case, the tumor becomes cancerous (figure 1.1).  
 
 
Figure 1.1: schematic representation of the multiple steps for macroscopic metastasis formation from 
primary tumor (from Saxena and Christofori, 2013) 
 
After the tumor diagnosis, the possibility of survival is one of the main indicators to assess 
the severity of the disease. The latter is strongly influenced by two tools: early diagnosis 
and therapy [Smith et al., 2015]. In the first case, thanks to the screening programs, the 
probability of an effectively recovery is higher. The effectiveness of the therapy, as well as 
the prognosis of the patient, are largely determined by the fact that a tumor remains 
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localized at the source site. If it metastasizes in other tissues or organs, the survival 
probability drastically decreases (i.e. the prognosis becomes unfavorable). The available 
treatment options are rarely able to cure a metastatic tumor. Metastasis management is 
difficult because cells, survived to the first therapeutic approach, may develop resistance to 
chemotherapy drugs or radiotherapy treatments. At present, there are no strategies to 
prevent or control the formation of metastases; usually the treatment has the only purpose 
of keeping under control the disease or reducing its symptoms. One of the main limitation 
of the chemotherapy treatments is the development of malignant cell’s resistance to one or 
more anticancer drugs which inevitably leads to a reduction of therapy effectiveness 
[Gottesman, 2002; Housman et al., 2014]. Moreover, most cytotoxic drugs don’t show 
specific action against tumor cells and may affect all patient's cells, especially those with 
fast proliferation such as bone marrow, lymphoid system, oral and gastrointestinal 
epithelium, the skin, the germinal epithelium of the gonads and the embryonic structures, 
causing numerous and serious side effects [Mi Kyung et al., 2012; Bae, 2009]. Just for 
these reasons and for their low therapeutic index the use of chemotherapeutic drugs in 
clinical approaches is strongly limited. These issues pushed toward the design of 
formulations for controlled drug delivery and targeting that are able to improve the 
biopharmaceutical profile of molecules with antitumor activity [Hardman et al., 2001; Peer 
et al., 2007; Torchilin, 2007]. 
 
1.4 Depot-forming formulations as drug delivery systems 
Depot-forming drug delivery systems is one of the most promising strategies to obtain a 
more effective and specific localized delivery of drugs able to minimize systemic side 
effect, thus improving the efficacy of the therapy [Kempe and Mäder, 2012; Fakhari and 
Subramony, 2015]. Despite the large number of potentially useful depot-formulation, most 
of them lead to irritation and local side effects and, therefore, only few systems based on 
implants, microparticles and hydrogels have found employment in clinical applications 
[Couvreur and Vauthier, 2006; Lukyanov and Torchilin, 2004; Tamilvanan, 2004; Thatte 
et al., 2005]. In the case of implants, a surgical procedure for its in vivo localization and 
removal is required. Examples of parenteral implants depot formulations, currently 
available on the market, are Vantas® (histrelin implant) and Viadur® (leuprolide acetate 
implant), approved from Food and Drug Administration (FDA) as palliative once-yearly 
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systems for to relieve the symptoms of the prostate cancer [Fowler et al., 2000; Moul and 
Civitelli, 2001]. Despite these kinds of systems offered a rapid drug administration, they do 
not obtain a good patient’s compliance. On the other hand, the possibility to obtain 
preformed systems using particles has made possible their administration without requiring 
any type of surgery. Moreover, the biodegradability of some polymers also avoids their 
removal after the release of the loaded drug(s) [Lee et al., 2010; Wischke and 
Schwendeman, 2008]. The main examples of these commercially available formulations 
are Leupron Depot® (leuprolide acetate for depot suspension) and Zoladex® (goserelin 
acetate), poly (lactic-co-glycolic acid) (PLGA) microspheres for peptide controlled release 
[Jiang et al., 2014; Park et al., 2014]. These formulations provide an administration of drug 
through a two chambers syringe system in which generally lyophilized microparticles are 
separated from the dispersion medium to prevent their degradation; the depot system will 
form after injection into the body. Compared with preformed implants systems, the 
microparticulate depot formulation requires a more complex and expensive manufacturing 
process. Moreover, the complex administration process could cause the injection of an 
incomplete dose of drug due to the partial dispersion of microparticles with the medium 
and/or the clotting of the syringe. To overcome these issues, alternatives in situ forming 
depot systems with low-cost manufacturing process, have been developed [Hatefi and 
Amsden, 2002; Packhaeuser et al., 2004]. The key parameter in this case is the low 
viscosity of the formulation prior to its injection; this promotes its injection trough syringe 
with standard diameter. After administrations, a solid or semi-solid depot system will form 
with body fluids contact and/or pH environment change, thus promoting a prolonged 
release of the loaded drug(s). By this way, an improved patient’s compliance can be 
achieved by using a less invasive and painful procedure. Currently, two in situ forming 
depots formulations have been approved by FDA for their practical use on market: 
Atridox® (doxycycline hyclate), a subgingival application for the treatment of chronic 
periodontitis in adults and Eligard® (leuprolide acetate), an injectable suspension for the 
palliative treatment of advanced (stage 2) prostate cancer [Javali and Vandana, 2012; Tunn 
et al., 2013]. Furthermore, polymeric hydrogels, such as commercially available 
belotero®, Juvéderm® and Restylane®, are also used as dermal fillers. Among the systems 
used as in situ depot formulation, thermo-responsive gels have attracted a great attention 
since they exhibit a drastic change of their physical properties with temperature [Ruel-
Gariepy and Leroux, 2004] (figure 1.2). In particular, if the transition temperature is 
appropriately arranged to be close the physiologic temperature, the matrices can be 
15 
 
administered as a viscous solution at 20 °C and, once at body temperature, are able to form 
in situ a weak gels.  
 
 
 
 
 
 
 
 
Figure 1.2: example of thermo-responsive gel forming depot formulation 
 
Examples of materials with temperature-dependent phase transition behaviors are 
represented by poloxamers (Pluronic®), amphiphilic tri-block copolymers with hydrophilic 
EO (ethylene oxide) units and a central hydrophobic PO (polypropylene oxide) portion 
(figure 1.3).  
 
 
 
 
 
 
Figure 1.3: poloxamers chemical structure 
 
Temperature (°C) 
Low viscous injectable 
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25 37 
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Poloxamers are frequently used as surfactants in many cosmetics, industrial and 
pharmaceutical applications since they are able to increase the solubility in water of 
slightly soluble molecules and the miscibility of molecules that are poorly mixed with each 
other’s [Alexandridis and Hatton, 1995; Santander-Ortega et al., 2006]. In water solutions, 
these amphiphilic tri-block copolymers can self-assemble into micellar structures above the 
critical micelle concentration (CMC) whereas, above the critical gelation concentration 
(CGC), are able to produce thermo-sensitive gels [Huynh et al., 2011; Pan and Yang, 
2011]. Although PEO-PPO-PEO like materials are not biodegradable, molecules with a 
molecular weight in the range from 10 to 15 kDa are generally filtered from the kidney and 
eliminated by the urine. As poloxamers, also modified cellulose derivatives can be used as 
depot formulations since they are able to form in vivo thermo-responsive gels. Indeed, if 
unmodified cellulose results insoluble in aqueous solutions, adding of hydrophilic groups 
allows their water solubilization and gelling at elevated temperatures (40-50 °C) 
[Kobayashi et al., 1999].  
Generally, depot-forming formulations, obtained by using polysaccharide, are preferred 
compared to systems obtained from other polymers, since they are biodegradable and 
biocompatible. These peculiar characteristics make them promising candidate for the 
development of in vivo depot forming systems for local drug administration. One of the 
polysaccharide commonly used as injectable in situ gelling agent is gellan gum. The latter 
is an anionic heteropolysaccharide, composing of glucose, glucuronic acid and rhamnose 
monosaccharides, obtained by microbial source. Gelrite, the deacetylated form, is the 
commercial product of gellan gum, marketed by Merck for glaucoma treatment as 
controlled release depot formulation (Timoptic). After its administration as low viscous 
solution to ocular mucosa, Gelrite is able to form a clear gel as result of electrostatic 
interaction with monovalent and divalent cations composing the tear fluid [Rozier et al., 
1989; Singh and Harikumar, 2012]. Moreover, polysaccharides can be blended with other 
polymers to lower their gelation temperature and/or increase the mechanical properties of 
the formed gel. For example, the addition of hyaluronic acid to methylcellulose aqueous 
solutions results in blends with typical rheological behavior of a viscous solution at room 
temperature and of a weak gel at body temperature (37 °C), thus making their use suitable 
as in situ depot forming formulations [Caicco et al., 2013]. 
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1.5 Nano-carriers based formulations as drug delivery systems 
Over the past two decades, nano-carriers based formulations for drug delivery and 
targeting have emerged as promising approaches to overcome the limitations of the 
common chemotherapy. A well-designed nano-system in terms of size and circulation half-
life, could promote a controlled release of the loaded drug(s), thus facilitating a better 
clinical result with reduced aggression compared to classical chemotherapeutics. 
Moreover, they are able to protect encapsulated drugs from the premature 
chemical/enzymatic degradation, improving their bioavailability into target sites and thus 
their therapeutic efficacy. Finally, one of the most challenging tasks in the design of nano-
carriers is an efficient drug accumulation into target sites. Indeed, they can passively 
accumulate into tumours taking advantage of enhanced permeation and retention effect 
(EPR), associated with increased permeability of blood vessels in the tumour area. This, in 
principle, increases the chance of drug accumulation in solid tumour tissues (figure 1.4 A). 
The key parameter in this case will be the particles properties; after administration, size, 
surface behaviours and composition will be crucial for the solubility and stability of the 
loaded drug(s), as well as for their interactions with cells [Aktaş et al., 2005; Au et al., 
2001; Ruoslahti et al., 2010]. On the other hand, drugs can be selectively delivered to the 
target site by an active targeting (figure 1.4 B). This strategy provides the functionalization 
of the carriers surface with specific ligands, such as proteins, antibodies and nucleic acids, 
able to recognize and bind specific receptors overexpressed by cancer cells, thus allowing a 
greater accumulation into tumour [Kommareddy et al., 2005].  
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Figure 1.4: carriers can reach tumour target site trough the leaky tumour vasculature by a passive targeting 
(A), or/and by an active targeting (B), after surface conjugation with ligands for receptors overexpressed by 
cancer cells (from Duhem et al., 2014)  
 
In this context polysaccharides represent a good candidates for the development of drug 
delivery systems, since they can be used both as structural or coating components of nano-
carriers based formulations. 
 
1.6 Polysaccharides as structural component of nano-carriers based formulations 
In recent years, an increasing number of research have been directed on the potential 
application of polysaccharide and their derivatives as structural component of nano-carriers 
based formulations for drug delivery. Depending on their structural properties, 
polysaccharides based nano-systems can be obtained by using different methods of 
production [Debele et al., 2016; Mizrahy and Peer, 2012]. Firstly, polysaccharides with 
negative or positive superficial charge are able to form polyelectrolyte complexes (PECs) 
after electrostatic interactions with oppositely charged macromolecules, by ionotropic 
gelation process. One of the main polymers suitable for gelation process is represented by 
chitosan (CHI), a natural cationic polysaccharide composed of D-glucosamine and N-
acetyl-D-glucosamine units with well-known biodegradability, biocompatibility and 
bioadhesiveness properties. CHI has a pKa value around 6-6.5 and is therefore easily 
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soluble in the acidic environment by protonation of the functional amine groups of the 
glucosamine units [Fan et al, 2012; Gan et al., 2005; Jonassen et al., 2012; Ramasamy et 
al., 2014]. The resulting positive charges makes it suitable for the ionotropic gelation 
process with an anionic counterpart, such as tripolyphosphate and/or hyaluronic acid [Nasti 
et al., 2009]. Commonly, oppositely charged macromolecules aggregate due to their high 
charge density fluctuation in solutions. Therefore, PECs formation and stability will 
depend on several parameters such as molecular weight, structure, charge density, mixing 
ratio of used polyelectrolytes, time of interactions between them as well as on the pH and 
temperature of the environmental conditions. In this case, the main advantage derived from 
the simple and easily up-scalable manufacturing process used to obtain PEC based nano-
carriers [Boddohi et al., 2009; Etrych et al., 2005; Hamman, 2010]. Thanks to their 
amphiphilic nature, some polysaccharides have a propensity to self-assemble in 
nanoparticulate structures (micelle) as the result of intra and inter-molecular interactions 
between their hydrophobic and hydrophilic segments in aqueous environment. The derived 
systems display unique features: they are able to encapsulate lipophilic drugs into 
hydrophobic core and, simultaneously, they expose hydrophilic moieties on the surface, 
resulting in increasing accumulation into tumor tissues [Myrick et al., 2014; Ozin et al., 
2009]. In addition, polysaccharide based nano-carriers can be obtained via cross-linking 
reaction, after adding of covalent or ionic cross-linking agents. Despite covalent cross-
linking agents allows to obtain more stable formulations thanks to the formation of 
covalent bonds between polymer chains, their usefulness in drug delivery is often avoided 
cause their possible undesirable interactions with the active molecule and their toxicity 
[Alvarez-Lorenzo et al., 2013; Janes et al., 2001; Jătariu et al., 2011].  
 
1.7 Polysaccharides as coating materials of nano-carriers based formulations 
After their injection into the body, nano-carriers are quickly eliminated from blood 
circulation since they are able to recognize and adsorb serum proteins (opsonins) on their 
surface. Protein adsorption promotes their fast aggregation and makes them easily 
recognizable by macrophages of endoplasmic reticulum (RES), resulting in their 
elimination and liver accumulation, where they may cause side effects [Lenaerts et al., 
1984; Leroux et al., 1995; Owens and Peppas, 2006]. The surface behaviours of the 
systems play a key role in the opsonisation process: carriers with hydrophilic moieties on 
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the surface, such as polyethylene glycol (PEG), possess stealth properties; they can prevent 
serum protein adsorption and thus prolong their bloodstream circulation. This, in principle, 
increases the chances of a preferential nano-devices accumulation in solid tumor tissues 
taking advantage of the EPR effect [Bhadra et al., 2002]. PEG is a biocompatible, 
biodegradable and non-toxic hydrophilic polymer able to form a protective layer around 
the carrier inhibiting the adsorption of serum proteins trough repulsion forces [Gref et al., 
1995; Sun et al., 2015]. Despite the physical stability and improved biocompatibility and 
residence time in blood circulation of the resulting PEGylated systems, this strategy is not 
suitable to prevent the non-specific interactions between drug delivery systems and 
proteins. Polysaccharides can be considered a promising alternative as coating materials 
since, most of them, are able to recognize and bind specific receptors expressed in tumor 
site, thus making it possible to achieve an active targeting. One of the most investigated 
polysaccharide as coating material is hyaluronic acid (HA). HA is a glycosaminoglycan 
(GAG) with a no branched polysaccharide chain, composed of about 2000-2500 
disaccharide units of D-glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (GlcNAc), 
linked through alternating β-1,4 e β-1,3 glycosidic bonds as well as intra-molecular 
hydrogen bonds, that stabilize its conformation [Almond, 2007]. It is present in all 
vertebrates and is one of the primary components of the ECM of the mammalian 
connective tissues, with proteoglycans and collagen fibers. HA has attracted a great deal of 
interest in the biomedical field for its hygroscopic and viscoelastic properties; the first 
allows the regulation of tissues hydration, while the latter makes it a good lubricant for the 
synovial fluid of the joints and for the vitreous humor of the eye [Angelova and Hunkeler, 
1999; Kogan et al., 2007; Liao et al., 2005]. The carboxyl groups of the glucuronic units at 
physiological pH are ionized giving it a high polarity with high solubility in water. In 
aqueous solution, thanks to the combination of different interactions, such as intra and 
inter-molecular hydrogen bonding, HA takes preferred network structures with peculiar 
properties: they can withstand at short-term deformations, thus exhibiting elastic properties 
and may flow at long-term deformations, showing viscous properties [Koo et al., 2005; 
Laurent and Fraser, 1992]. HA is also involved in cellular motility, adhesion of cells to the 
extracellular matrix, cell proliferation and differentiation. Due to its biocompatibility and 
biodegradability, its chemical-physical properties as well as the ease of chemical 
functionalization, HA has attracted a great deal of attention and has been extensively used 
in several biomedical applications, such as regenerative medicine and drug delivery. In 
recent years, it has been proposed as ligand for an active targeting to cancer cells. Indeed, 
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it is able to selectively bind CD44 and RHAMM receptors, overexpressed on the surface of 
some cancer cells, such as prostate, breast or colon cancer cells, and glioblastoma cells 
[Gotte and Yip, 2006; Ossipov, 2010]. HA, once bound to its receptors, activates an 
internalization mechanism through receptor-mediated endocytosis; by this way, it is 
possible to promote cells internalization of bound-HA drugs or drugs loaded in HA-coated 
systems, thus increasing their concentration into target cells and so their therapeutic 
efficacy [Ahrens et al., 2001; Auzenne et al., 2007; Isacke and Yarwood, 2002]. Moreover, 
recent studies have evidenced the HA targeting ability to tumor cell subpopulations with 
self-renewal capacity, known as cancer stem cells (CSCs), responsible of invasion, 
metastasis and therapeutic resistance phenomenon which appears in tumors [Jaggupilli and 
Elkord, 2012]. In particular, HA-coated systems are able to bind CD44 receptor over-
expressed on CSC surface, inhibiting their self-renewal ability and enhancing apoptosis 
and necrosis, thus resulting in a reduction of tumor growth [Dosio et al., 2016].  
 
 
Figure 1.5: example of HA modified NP for targeted drug delivery to CD44 overexpressing cancer cells 
trough receptor-mediated endocytosis  
 
Another polysaccharide that has recently been evaluated as tumor-active targeting ligand is 
enoxaparin (Enox). Enox is a kind of low molecular weight heparin (LMWH), obtained by 
chemical or enzymatic depolymerization of unfractionated heparin (UFH). UFH belongs to 
GAG’s family and it is constituted by repeating disaccharide units of N-acetyl-
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glucosamine and L-iduronic acid, with a molecular weight in the range from 3 to 30 kDa 
[Afratis et al., 2012; Francis et al., 2006]. The high degree of sulfonylation on different 
amino and hydroxyl units of disaccharide, make UFH a molecule with a very high negative 
charge;  this is crucial for its electrostatic interaction with some components of ECM, such 
as growth factors, proteins, cytokines and chemokines [Karamanos et al., 1997; Liang and 
Kiick, 2014; Militsopoulou et al., 2002]. Thanks to the proteins-binding ability, it has a 
key role in ECM organization, contributing to the interactions between cells and ECM, 
thus promoting cells adhesion and migration [Theocharis et al., 2014; Theocharis et al., 
2015]. For decades, UFH has been used as blood anticoagulant in clinical practice for 
thromboembolic disorders treatment, as result of its ability to bind antithrombin [De Kort 
et al., 2005]. However, long-term clinical use of UFH is limited, since it can cause several 
side effects, among which hemolysis and thrombocytopenia [Lapierre et al., 1996]. For this 
reason, several LMWHs with range size between 4000-6000 Da and with low toxicity were 
produced and their alternative use in therapy were investigated [Belting, 2014; Yang et al., 
2015]. Various LMWHs have been commercially approved from FDA. In particular, Enox 
(Lovenox®) was approved for medical use in 1993 and is currently used for the treatment 
and the prevention of deep vein thrombosis, pulmonary embolism and in patients with 
heart attacks and acute coronary syndrome [WHO, 2016].  
 
 
 Figure 1.6: Enox chemical structure  
 
Thanks to their UFH similar biological/chemical properties, LMWHs show the same or 
improved anticoagulant and anti-inflammatory activity compared to UFH. Recent studies 
demonstrated that UFH, and many of its LMWH derivatives, exhibit anticancer property in 
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different types of cancers [Gomes et al., 2015; Kozlowsky and Pavao, 2011; Niers et al., 
2007; Nikos et al., 2017]. It could be probably related to their ability to bind various 
molecules involved in the metastasis formation, such as heparinase, over expressed in 
tumors. The latter is an endoglycosidase that stimulate the degradation of the ECM by 
cleaving the heparin sulfate chains thus promoting easier tumor cells extravasations 
[Bouris et al., 2015]. They can also inhibit the activity of P and L-selectins, which are 
involved in cell-cell interactions and of fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF), involved in angiogenesis process [Läubli and Borsig, 
2010]. Moreover, Enox and others LMWHs derivatives are able to selectively bind 
fibrinogen-derived products and angiogenic growth factors over expressed in the stroma of 
some tumors and not in normal tissues. These interactions allow enhancing the targeting 
ability of Enox-coated systems and their internalization into cancer cells. 
 
1.8 Aim of the thesis 
The overall aim of this thesis was to design, produce and characterize innovative 
formulations based on polysaccharides for tumors treatment. To this aim, two different 
strategies were pursued. The first one concerned the design of in situ forming depot 
systems suitable for local administration into or close to the tumor tissue. 
In particular, the first part of the thesis, presented in the chapter 2, deals with the 
production of thermo-responsive gels acting like a “metastasis traps” for the diversion of 
CXCR4
+
 circulating tumor cells. This study is based on the evidence that the CXCL12-
CXCR4 axis seems to have a critical role in the metastasis formation since cancer cells that 
express the receptor CXCR4, are attracted towards tissues that release CXCL12 becoming, 
therefore, a target for metastasis formation. Thus, the thermo-responsive gels were loaded 
with CXCL12 in order to create a concentration gradient of the chemokine near the site of 
administration/injection. By this way the gels can diverge and capture CXCR4
+
 circulating 
tumor cells and, in particular, the cells disseminated from primary tumor, thus inhibiting 
cancer cells migration in other organs and tissues and, consequently, preventing the 
formation of metastasis. Different thermo-responsive gels were designed, with and without 
HA, and mechanical optimized to allow the permeation of the CXCR4
+
 tumor cells into the 
gels and to capture them for a time frame sufficient to inhibit their migration in other sites. 
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CXCR4
+
 human T-Leukemia cells were used to evaluate the biological effectiveness of the 
formulations by examining the cells migration toward the gels and their 
presence/permanence into the gels by microscopy and flow cytometry analysis (FACS). 
The in vitro cellular experiments were carried out in collaboration with the National 
Cancer Institute “G.Pascale” Foundation of Naples. 
The second part of this thesis, concerned the use of polysaccharides as structural 
component and as coating materials for different types of nano-carriers, such as 
polyelectrolyte complexes (PECs), polymeric nanoparticles (NPs), and self-emulsifying 
drug delivery systems (SEDDS). 
In particular, the second work of the thesis presented in the chapter 3, concerned the use of 
the polysaccharide CHI as structural component for the development of PECs, for 
doxorubicin (Doxo) and zoledronic acid (Zol) combined therapy to overcame multidrug 
resistance against Doxo resistant tumors. PECs were prepared through ionotropic gelation 
technique, exploiting the electrostatic interactions between opposite charge polymers. By 
this way, it is possible to direct PECs self-assembly with a simple and easily scale-up 
method, avoid organic solvents and chemical reactions between polymers. The influence of 
some experimental parameters was evaluated in order to optimize PECs preparation in 
terms of size and polydispersity index. Mean diameter, polydispersity index and -
potential values were studied over the time, in order to evaluate their stability. Doxo and 
Zol encapsulation efficiency as well as PECs yield of preparation, were analyzed. 
Moreover, HA-coated PECs were also developed. Finally, in vitro studies were carried out 
on osteosarcoma, Doxo-resistant osteosarcoma and breast cancer cell lines, to assess the 
synergism between Doxo and Zol, the restoring of Doxo sensitivity and the targeting of 
CD44-overexpressing cells by using HA-coated PEC. The in vitro cellular experiments 
were carried out in collaboration with the Department of Biochemistry, Biophysics and 
General Pathology of the University of Campania “Luigi Vanvitelli”. 
As far as polymeric NPs are concerned, in the third work of the thesis presented in the 
chapter 4, we investigated the possibility to direct a spontaneous arrangement of the tumor 
targeting polysaccharide HA on PLGA NPs loaded with the anticancer drug irinotecan. 
The basic idea was to bind HA shell on NPs surface by means a lipophilic gradient 
between the oil and water phases of the emulsions used for the NPs production, using 
poloxamers as a bridge between the hydrophobic cores made up of PLGA and the 
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hydrophilic HA shell. By this way, it was possible to obtain spontaneously HA-coated NPs 
by a single step process easily to scale-up for industrial applications. The obtained NPs 
were then characterized for their technological properties and a calorimetric study as well 
as ELISA test were performed, to support the hypothesis of polymer assembly in NPs 
architecture. In vitro biological studies were carried out to verify NPs ability to target 
CD44 receptor, on CD44-overexpressing breast carcinoma cells. The in vitro cellular 
experiments were carried out in collaboration with the Institute for Polymers, Composites 
and Biomaterials (IPCB) of the National Research Council (CNR). 
As for SEDDS, the aim of the fourth work of the present thesis, presented in the chapter 5, 
was the in vitro evaluation of their tumor targeting ability, once provided them of an Enox 
coating shell. This work was carried out during my stay abroad in Austria at the 
Department of Pharmaceutical Technology of Innsbruck under the supervision of Professor 
Andreas Bernkop Schnürch. These systems are able to spontaneously emulsifying after the 
exposure with body fluids, producing a transparent and stable nanoemulsion. This makes 
them easy to manufacture and to scale-up for large-scale production. SEDDS surface were 
then coated with Enox. This was achieved by firstly preparing an amphiphilic conjugate 
able to direct the spontaneous exposition of Enox moieties on SEDDS surface. The 
possibility of Enox coated formulations to be sterilized by filtration and their 
hemocompatibility needed for administrated by parenteral route, were evaluated. The in 
vitro cell uptake studies of SEDDS decorated with Enox, compared with uncoated 
formulation, were carried out on both human breast adenocarcinoma and human epithelial 
colorectal adenocarcinoma cell lines.  
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CHAPTER 2  
Engineering of thermoresponsive gels as a fake metastatic niche toward 
the capture of CXCR4
+
 circulating tumor cells 
 
ABSTRACT 
Chemoattraction through the CXCR4-CXCL12 axis has been shown to be an important 
mechanism to direct circulating tumor cells toward distant sites. In this panorama, a fake 
metastatic niche made up of a gel loaded with CXCL12 was realized. The gel is able to 
create a steep concentration gradient of the chemokine in the proximity of the site of 
administration/injection, aimed to divert and capture the circulating CXCR4
+
 tumor cells. 
To this aim, different thermoresponsive gels based on methylcellulose (MC) or 
poloxamers, with and without HA, were designed, loaded with CXCL12 and their 
mechanical properties correlated with the ability to attract and capture in vitro CXCR4
+
 
cells were evaluated. 
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2.1 Introduction 
Metastasis is the dissemination of cancer cells away from the site of origin. The process 
develop through several stages, such as: (i) loss of cell-cell contact; (ii) degradation of the 
basal lamina by malignant cells, resulting in local invasion; (iii) intravasation of cancer 
cells into the bloodstream and/or lymphatic system; (iv) migration of cancer cells in other 
organs and tissues; (v) creation of a pre-metastatic niche where metastasis may form if a 
permissive microenvironment for tumor cell colonization and proliferation is present
 
[Arvelo et al., 2016; De la Fuente et al., 2015]. Chemoattraction through the CXCR4-
CXCL12 axis has been shown to be an important mechanism to direct circulating tumor 
cells toward the host organ [Liu et al., 2016]. CXCL12, also known as stromal derived 
factor (SDF), is a highly effective chemokine with a marked action as chemotactic factor 
for T-lymphocytes and monocytes. In addition, it induces intracellular actin polymerization 
in lymphocytes, a process that is thought to be a prerequisite for cell motility [Bleul et al., 
1996]. As result of alternative splicing of the same gene, it is secreted as six isoforms; 
CXCL12/ɑ is the predominant form, present in almost all tissues [Yu et al., 2006]. In 
particular, while during embryogenesis, CXCL12 regulate the migration of hematopoietic 
cells from fetal liver to bone marrow and the development of blood vessels, in adults, it 
plays an important role in carcinogenesis process. Indeed, it is involved in angiogenesis by 
calling up endothelial progenitor cells (EPCs) from the bone marrow through a CXCR4 
receptor dependent system [Zheng et al., 2007]. Also CXCL12 plays a key role in tumor 
metastasis: cancer cells expressing the CXCR4 receptor are attracted toward tissues 
releasing CXCL12 becoming, therefore, a target for metastasis formation [Müller et al., 
2001]. While in many healthy tissues the expression of the CXCR4 receptor is low or 
absent, it was proved to be present in over 23 types of cancers, including breast, ovarian, 
prostate cancer and melanoma. Moreover, the CXCR4’s expression in cancer cells seems 
to be related to tissues metastasis containing a high concentration of CXCL12 [Sun et al., 
2010]. Despite the importance of the CXCL12-CXCR4 axis in tissue regeneration and in 
cell migration induced by chemotaxis, the use of CXCL12 in clinical use is limited by its 
short half-life and its highly time-dependent expression [Murphy et al., 2007].  
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2.2 Aim of the work 
In this context, we investigated on the use of a fake metastatic niche consisting of a gel 
loaded with CXCL12 and able to create a steep concentration gradient of the chemokine in 
the proximity of the site of administration/injection, therefore diverting and capturing the 
circulating CXCR4
+
 tumor cells. Thus, we have designed different thermoresponsive gels 
based on MC or poloxamers, with or without the addition of the polysaccharide HA. The 
gels were loaded with CXCL12 and their mechanical properties have been correlated with 
the in vitro ability to attract and capture CXCR4
+
 human T-leukemia cells. Thermo-
responsiveness is a pivotal attribute in this context; in particular, the gels were designed to 
have a lower critical solution transition temperature (LCST) close to the physiologic 
temperature. Thus, the matrices can be administered by means of a syringe being a viscous 
solution at 25 °C but, once at body temperature, they are able to form in situ a gel with 
mechanical properties suitable to capture CXCR4
+
 circulating tumor cells [Klouda and 
Mikos, 2008]. 
 
2.3 Materials and methods 
2.3.1 Materials 
MC (viscosity: 4,000 cP) was purchased from Sigma (Milano, Italy). Poloxamers (Polox) 
used, designed with variable numbers of oxyethylene (a) and oxypropylene (b) units, were 
F127 (a = 100 and b = 65) and F68 (a = 76 and b = 29), obtained from Lutrol (Basf, 
Germany). Medium molecular weight (850 kDa) HA was supplied by Novozymes 
Biopharma (Bagsvaerd, Denmark). Potassium chloride (KCl) from Carlo Erba (Milano, 
Italy), dibasic sodium phosphate (Na2HPO4), sodium chloride (NaCl) from Sigma-Aldrich 
(St. Louis, USA) were used. CXCL12/ɑ was purchased from R&D systems (Minneapolis, 
USA). 
 
2.3.2 Preparation of MC and MC-HA gels 
Gel made of bare MC was prepared by dissolving MC (2% w/v) in phosphate buffer saline 
(PBS, 120 mM NaCl, 2.7 mM KCl, 10 mM phosphate salts, pH=7.4), as previously 
reported
 
[Mayol et al., 2014]. Briefly, the solvent was divided into two aliquots of equal 
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volume: one was brought at 0 °C and the other one was heated until it reached the boiling 
point. MC was slowly solubilized in the hot solvent and then the cold solvent was added 
under magnetic stirring for about 4 hours, in an ice bath. The resultant solution was kept at 
4 °C overnight. MC-HA gel was obtained by simply adding HA (0.1% w/v) into MC gel 
and mixing the resultant solution for one hour. For in vitro migration assay, CXCL12 was 
merely dispersed into the gel (0,00003% w/v). 
 
2.3.3 Preparation of Polox and Polox-HA based gel 
Polox gel was prepared as previously described with some modifications
 
[Mayol et al., 
2011]. Briefly, Polox F127 and F68 (21.43% w/v each) were mixed in distilled water under 
magnetic stirring, in an ice bath, until a clear solution was obtained. For complete 
solubilization, the solution was kept at 4 °C overnight. Polox-HA based formulation was 
obtained by adding HA (0.1% w/v) within the Polox solution under continuous stirring. 
The gels were stored at 4 °C until use. For in vitro migration assay, CXCL12 was merely 
dispersed into the gel. 
 
2.3.4 Cell culture 
CCRF-CEM, named CEM cells in the following, were grown in Roswell Park Memorial 
Institute (RPMI)-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, Utah, 
USA) with 10% fetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium pyruvate, 
penicillin and streptomycin (50 µg/mL each). 
 
2.3.5 Cell migration assay 
Cell migration was assayed in 24-well Transwell
®
 chambers (Corning Inc., Corning, NY) 
using inserts with 6.5-µm pore membrane. CEM cells, pre-stained with live dye green cell 
tracker (CellTracker Green CMFDA, Invitrogen, USA), were placed in the upper chamber 
(2.0 × 10
5
cells/well) in the presence of a migration medium made of a 0.5% w/v bovine 
serum albumin (BSA) solution in 500µL RPMI. The lower chamber contained also the gels 
with or without CXCL12, bare cell culture medium as a control or CXCL12 solutions in 
41 
 
RPMI at 300 ng/mL. After 4 hours of incubation, cells on the upper surface of the filter 
were removed using a cotton wool swab; the membrane was then fixed in 4% 
paraformaldehyde for 15 min and the cells migrated toward the lower surface of the 
membrane were stained with 4,6-diamidino-2phenylindole (DAPI, 1:25000, AbD Serotec, 
UK), photographed and visually counted in 10 random selection of fluorescent microscope 
fields (Carlo Zeiss, Axio Scope.A1). Triplicate experiments were carried out. The amount 
of migrated cells was estimated through the migration index, defined as the ratio between 
number of migrating cells toward BSA containing media (CXCL12-loaded gels/gels or 
CXCL12/BSA). 
 
2.3.6 Rheological experiments 
The rheological properties of the gels were evaluated on a rotational rheometer (Malvern 
Kinexus) using a cone and plate geometry. In particular, the viscoelastic response of each 
formulation was evaluated by small-amplitude oscillatory shear tests. Briefly, each 
experiment was performed at 25 °C and 37 °C, in the 0.1 to 10 Hz oscillation frequency 
range with a shear strain fixed at which linear viscoelasticity is attained. The solutions 
were placed between the two plates with a gap < 1 mm. Thus, the shear storage or elastic 
modulus (G’) and the shear loss or viscous modulus (G’’) were measured as a function of 
frequency, which respectively characterize the solid-like contributions or the energy stored 
in the material during deformation and fluid-like contributions, or energy dissipated as 
heat, to the measured stress response. The value of G’ allows estimating the features of the 
network structure. As G is proportional to the sum of the elastic contribution of the number 
of entanglements
 [D’Errico et al., 2008], it is possible to determine the average molecular 
weight of the polymer segments between two entanglements (Me), through the Flory 
theory: 
𝑀𝑒 =
𝑅𝑇𝑐
𝐺
 
where RT is the thermal energy and c is the polymer concentration.  Using the “equivalent 
network model” it is possible to estimate Dn, which is the average distance between the 
entanglements of polymer network: 
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𝐷𝑛 = √
6 ∙ 𝑀𝑒
𝜋 ∙ 𝑐 ∙ 𝐴
3
 
where A is Avogadro constant [Flory, 1953]. 
 
2.3.7 In vitro gel dissolution kinetics 
The in vitro dissolution kinetics of the obtained gels were evaluated by loading each them 
(1 mL) in a dialysis membrane (Spectra/Por® Biotech Cellular ester; molecular cut-off 12-
14 kDa) and immersing them in 50 mL of PBS (pH=7.4), in a shaker bath at 37 °C. At 
predetermined time intervals, the gel-loaded membranes were recovered, washed three 
times for 30 minutes time with water to eliminate excess salts, dried for 3 hour at 25 °C 
and finally weighed. The residual mass of the gels was calculated as:  
𝑚𝑅 =
𝑚(𝑡 = 𝑖)
𝑚(𝑡 = 0)
𝑋100 
where t=i is gel mass at a given time, while t=0 is the initial gel mass. All experiments 
were performed on at least three independents samples.  
 
2.4 Results  
2.4.1 CXCL12 released from gels is biologically active 
The biological activity of the released CXCL12 was defined through CEM cell migration. 
The number of cells labelled with Green Cell Tracker migrated onto the membrane were 
counted using fluorescence imaging. The lower chamber contained CXCL12 in 0.5% 
BSA-culture medium, CXCL12-loaded gels or empty gels. Cells (2.0 x10
5
 cells/well) were 
placed in the upper chamber and allowed to migrate toward CXCL12 (300 ng/mL), empty 
or CXCL12 (300 ng/mL)-loaded MC, MC-HA, Polox, Polox-HA in 0.5% BSA medium 
for 4 hours. The CXCL12 loaded gels induced higher CEM cell migration compared to 
corresponding empty gels (figure 2.1, Upper panel). The number of cells migrated to the 
lower chamber was also evaluated by flow-cytometry. In accordance, the number of 
migrated cells was higher in the wells containing CXCL12 loaded gels compared to empty 
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gels (figure 2.1, Lower panel). These results demonstrate that CXCL12 released from 
loaded gels is biologically active being able to attract CXCR4
+
 cells.  
 
 
Figure 2.1: CXCL12 released from loaded gels MC, MC-HA, Polox, Polox-HA induced CEM cell 
migration. Upper: Migration was examined in CEM cell line in 24-well plates. Cells (2.0 x10
5
cells/well) 
were placed in the upper chamber and allowed to migrate toward CXCL12 (300 ng/mL), empty or CXCL12 
(300 ng/mL)-loaded MC, MC-HA, Polox, Polox-HA in 0.5% BSA medium for 4 hours. The cells (number of 
cells migrated through the membrane) were counted in ten different consecutive high power fields 
(magnification 200X). The results are expressed as migration index compared to BSA cells migration. Each 
column represents the mean ± S.D. (n=3). Statistical significances were calculated by student’s t-test.            
* p<0.05, *** p<0.001 CXCL12 vs BSA or gel+CXCL12 vs gel. Lower: CEM cells migrated into the lower 
chamber were counted by flow cytometry. Statistical significances were calculated by student’s t-test. 
**p<0.01, *** p<0.001 CXCL12 vs BSA or gel+CXCL12 vs gel 
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2.4.2 CXCL12 embedded gel is biologically active 
The ability of the gels to recruit and capture tumor cells was assessed evaluating CEM 
cells migrated into the gels. In figure 2.2 (Upper and Intermediate panel), higher number of 
cells were detected on the bottom side of the filter comparing Polox+CXCL12 and Polox-
HA+CXCL12 gels (panel C-D) versus Polox and Polox-HA gels (panel A-B). Moreover, 
higher cell number migrated to the bottom side of the filter toward the MC+CXCL12 and 
MC-HA+CXCX12 gels (panel G-H) with respect to MC and MC-HA gels (panel E-F). By 
comparing the two gels (Polox and MC), the Polox+CXCL12 (panel C) and the Polox-
HA+CXCL12 (panel D) gels were overall more efficient in inducing transmembrane 
migration. Conversely, by evaluating the cells trapped into the gels, a higher number of 
cells migrated into the MC and MC-HA gels embedded with CXCL12 (figure 2.2, Lower 
panel). As it is shown MC+CXCL12 gels (C) were more efficient compared to MC-HA 
gels (D) (figure 2.2, Lower panel). In the Polox or Polox-HA gels no cells were detected 
into the gels (data not shown). To summarize, only MC and MC-HA gels embedded with 
CXCL12 captured CEM tumor cells although CXCL12-loaded gels MC, MC-HA, Polox 
and Polox-HA induced CEM cell migration. 
 
    
 
F 
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Figure 2.2: CEM cell migrated into MC and MC-HA gels. Upper panel: Representative images of filters 
displaying migrated CEM cells. Migration was examined in CEM cell line in 24-well plates. Cells (2.0 
x10
5
cells/well) were placed in the upper chamber and migrated toward CXCL12 (300 ng/mL), empty Polox 
(A), Polox-HA (B), MC (E), MC-HA (F), or CXCL12 (300 ng/mL)-loaded Polox (C), Polox-HA (D), MC 
(G), MC-HA (H). Intermediate panel: The quantitative results of migrated cells on filters. The cells 
(evaluated as number of cells migrated on the membrane) were counted in ten different consecutive high 
power fields (magnification 200X). The results are expressed as the migration index respect to basal 
migration of cells in BSA. Each column represents the mean ± S.D. (n=3). Statistical significances were 
calculated by Student’s t-test. ** p<0.01, *** p<0.001 CXCL12 vs BSA or gel+CXCL12 vs gel. Lower 
Panel: Representative images of CEM cells inside the gel MC (A), MC-HA (B), MC+CXCL12 (C) and MC-
HA+CXCL12 (D) after 4 hours of migration. In the Polox or Polox-HA gels no cells were detected into the 
gels (data not shown) 
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2.4.3 Rheological studies 
Figures 2.3 and 2.4 display the results of rheological analyses of MC-based and Polox-
based gels, in the presence or absence of HA. In particular, the storage shear modulus (G’) 
and the loss shear modulus (G’’) are reported as a function of oscillation frequency at two 
different temperatures (25 °C and 37 °C). It can be observed that MC-based systems show 
qualitatively similar mechanical behaviors. In particular, at 25 °C, G'' is higher than G' in 
all cases and, therefore, the systems present a viscous/liquid-like behavior in all the 
analyzed frequency range. At 37 °C, however, the mechanical behavior is reversed and G' 
> G'' by roughly one order of magnitude at all frequencies; therefore, a gel was formed, 
with both viscoelastic moduli being basically frequency-independent.  
Moreover, in the presence of HA within MC systems, the mechanical properties of MC 
gels were significantly increased at 37 °C, therefore indicating the formation of a strong 
gel; on the contrary, at 25 °C, the mechanical spectra of the viscous liquids showed a 
qualitatively similar trend with the frequency. As depicted in figure 2.4, also the Polox gels 
showed a similar, temperature-dependent behavior. However, in this case, the strength of 
the gel was affected by the presence of HA to a lesser extent, showing an elastic modulus 
of approximately 10
4
 Pa inherently unaffected by the frequency in the explored range, for 
both HA-containing and HA-free formulations. 
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Figure 2.3: mechanical spectra of MC (A) and MC-HA (B), at 25 °C and 37 °C 
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Figure 2.4: mechanical spectra of Polox (A) and Polox-HA (B), at 25 °C and 37 °C 
 
The calculated Me and Dn of the gels are reported in table 2.1. MC–based gel has shown 
the highest values of Dn, with a significant decrease after addition of HA in the 
formulation. Conversely, Polox formulations have been shown to possess a lower value of 
Dn, irrespective of HA addition.  
 
Formultion 
[Polymer] 
(% p/v) 
[HA]
*
 
(% p/v) 
G’ 
(Pa) 
Me×10
6
 
(g/mol) 
Dn 
(nm) 
MC 2 - 75.2 97.6 54 
MC-HA 2 0.1 515 15.0 28 
Polox 42.9 - 3600 43.7 15 
Polox-HA 42.9 0.1 3990 39.5 14 
Table 2.1: network parameters of MC- and Polox-based different gels. G’ is the value of the elastic modulus 
at 0.1 Hz, 37 °C. 
*
Overall HA percentage in the final gel 
 
2.4.4 In vitro dissolution kinetics 
The dissolution kinetics of the gels, expressed as percentage of gel residual mass as a 
function of the time of immersion in PBS (pH=7.4) at 37 °C, are shown in figure 2.5. As it 
can be seen from the chart, MC and MC-HA gels dissolve more slowly than Polox gel. It 
must also be observed that the presence of HA in the MC formulation seems slightly 
48 
 
increase the rate of the gel dissolution. Instead the addition of HA to Polox gels strongly 
delays the in vitro dissolution kinetics. 
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Figure 2.5: dissolution kinetics of different gels 
 
2.5 Discussion 
To date, despite the avalanche of new therapeutic regimens in cancer therapy, 
metastases are the primary determinants of mortality in patients
 
[Yang et al., 2014]. 
Metastasis targeting, a recent focus in cancer research, has been often addressed based on 
targeting specific genetic alterations in primary tumors. The outcomes of this have been, 
however, somehow unsatisfactory, mainly because of the genetic instability of metastatic 
tissues, which leads, in to mid-long term, to the selective outgrowth of therapy-resistant 
cells over sensitive ones [Cifone and Fidler, 1981; Fidler and Kripke, 2015]. Therefore, in 
this work we propose a possible, new paradigm to strive for the targeting of circulating 
metastases, to circumvent their genetic instability-driven elusiveness as a therapeutic goal. 
Actually, to the best of our knowledge, there are no scientific reports dealing with gel 
systems loaded with chemoattractants so as to work as metastasis traps. In this study, we 
have produced a novel device made up of a thermo-responsive gel loaded with CXCL12 to 
divert and capture circulating CEM cells, thus inhibiting their migration in other organs 
and tissues and, consequently, avoiding the establishment of a metastatic colony. All the 
formulated gels showed a thermo-sensitive behavior, with a gelification temperature 
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around body temperature, while being a viscous solution at room temperature
 
[Mayol et 
al., 2011; Mayol et al., 2014]. This is a pivotal feature for syringeability, which is a crucial 
parameter of parenteral systems and, even more importantly, the ability to form gels at 
physiological temperature. Seemingly, the rheological properties of the gels at 37 °C 
influenced the capacity of CEM cells to migrate into the gels. Indeed, CEM cells are able 
to feel a CXCL12 chemotactic stimulus and cross the transwell membrane, whose pore size 
is 8 µm, irrespective of gel formulation. On the other hand, fluorescence microscope 
images have shown that, in MC-based systems, the presence of CXCL12 prompts cell 
migration toward the gels, this effect being more apparent when HA was present.  In the 
case of Polox-based gels, both in the presence and absence of HA, the migration indexes 
were higher than in the case of MC-based systems. Despite this, cells were not found 
within the Polox-based gels, therefore indicating that, after the noticeable initial trigger to 
cell migration, cell invasion ability in Polox-based gels was thwarted. Actually, cell ability 
to migrate is highly dependent on the stiffnes of the matrix in which migration occurs
 
[Da 
Silva et al., 2010; Engler et al., 2006]. More in detail, the amount of migrating cells is 
dictated by the cell ability to polarize in the sense of creating an asymmetric configuration 
of its subdomains resulting in cell movement activated by a protrusion–contraction 
sequence. In turn, cell polarization is influenced by matrix rigidity, and this results into 
durotaxis phenomenon
 
which is the alignment of actin and myosin filaments along a 
gradient of matrix stiffness [De et al., 2008; Raab et al., 2017; Saez et al., 2007; Zemel and 
Safran, 2007]. Specifically, the traction forces involved in the contractile events of the 
filaments which trigger cell movement are higher when the cells experience stiffer matrices 
[Lam et al., 2011; Mitrossilis et al., 2010]. In actual fact, the elastic modulus of Polox-
based gels at 37 °C was higher than that of MC-based systems in all the range frequency 
analyzed, and this is congruent with the observed high values in the migration index for 
such gels compared to MC-based systems. Results shown in figure 2.2 indicate that CEM 
cells are able to migrate within MC-based gels, while no cells were detectable within 
Polox-based matrices. This can be reasonably ascribed to the capacity of the CEM cells to 
diffuse inside the gels pores. Since gel pores (i.e. the mesh size of the gels) were found to 
be smaller then CEM cell dimensions (~15 m), cell diffusion/penetration into the gels can 
be influenced by the ability of the polymer chians to disentagle each-other, thus enlarging 
their pores and so to the different viscous components of the various gels. In particular, as 
illustrated by rheograms in figure 2.4, at 37 °C and at low stress frequencies, the measured 
G” values of Polox-based gels are more than one order of magnitude higher compared to 
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G” values of MC-based gels. This can be considered a detriment to cell movement in the 
gel, which basically occurs via cavity-to-cavity steps. Indeed, it has been recently 
suggested that cell deformability, possibly combined with the deformation of the scaffold 
being intruded, is a limiting feature for migration [Da Silva et al., 2010]. 
The results shown in this work suggest that CEM cells are sensitive to both chemical and 
mechanical gradients, and that an optimization of the gel systems should probably take into 
account the possible existence of a limiting viscosity above which a gel matrix hampers the 
deformation of its pores therefore resulting in a significant impairment of cell migration. 
 
2.6 Conclusions 
The use of a fake metastatic niche to divert and capture CXCR4
+
 circulating tumor cells 
can be helpful in capturing these target cells and possibly reducing/inhibiting the formation 
of metastasis. The optimized combination of chemical gradient and knowledge of durotaxis 
phenomenon is probably required to maximize the capturing ability of the tested gels. This 
approach, associated to typical surgical and chemotherapeutic clinical therapies, could be, 
in our opinion, very useful in cancer management. Further studies will be done to assess 
also in vivo the gel capability to divert CXCR4
+
 circulating tumor cells.  
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CHAPTER 3  
Chitosan-based polyelecrolyte complexes for doxorubicin and zoledronic 
acid combined therapy to overcame multidrug resistance  
 
ABSTRACT 
The aim of the present work was to develop PECs encapsulating Doxo and Zol for 
combined therapy against Doxo-resistant tumors. PECs were prepared by ionotropic 
gelation technique. The influence of some experimental parameters was evaluated in order 
to optimize the PECs in terms of size and polydispersity index. To study PEC stability, size 
and -potential were monitored over the time. Moreover, HA-coated PECs were also 
developed. Finally, in vitro studies were carried out on wild type and Doxo-resistant cell 
lines, to assess both the synergism between Doxo and Zol, as well as the restoring of Doxo 
sensitivity. Moreover, targeting of CD44-overexpressing cells by using HA-coated PEC 
was also tested. Polymer concentration, incubation time and use of a surfactant were found 
to be crucial to achieve small size and monodisperse PECs. Doxo and Zol, only when 
encapsulated in PEC, showed synergism antiproliferative effect in all the tested cell lines. 
Moreover, the incubation of Doxo-resistant cell lines with Doxo/Zol co-encapsulating PEC 
resulted in restoration of Doxo sensitivity. Finally, in CD44-overexpressing cells, the 
addition of HA on PEC surface slightly enhanced the cytotoxicity of PEC encapsulating 
Doxo, but not of PEC co-encapsulating Doxo and Zol. PECs co-loaded with Doxo and Zol 
can be considered a promising approach to enhance Doxo cytotoxicity, overcaming drug 
resistance in Doxo-resistant cancer cells. 
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3.1 Introduction 
One of the main limitation of the chemotherapy treatments is the development of 
malignant cell’s resistance to one or more anticancer drugs; this process is known as 
"multidrug resistance" (MDR) which inevitably leads to a reduction of therapy 
effectiveness [Krishna and Mayer, 2000; Liscovitch and Lavie, 2002; Stavrovskaya, 2000; 
Szakács et al., 2006]. Generally, hydrophobic and amphipathic natural molecules, such as 
anthracyclines (e.g. Doxo) are more prone to develop resistance compared to other 
substances [Calcagno and Ambudkar, 2010; Thomas and Coley, 2003]. It is well known 
that the over-expression of some proteins of the efflux pumps ATP-binding cassette (ABC) 
family, is one of the major causes of the MDR [Choi, 2005; Gottesman and Pastan, 1993; 
Gottesman et al., 2002]. One of the main components of the ABC family is represented by 
P-glycoprotein (P-gp), also known as MDR protein 1(MDR1). P-gp is normally expressed 
in different normal tissues, such as kidney, liver, pancreas and colon where it is involved in 
the extrusion of neutral or weakly basic amphipathic substances penetrated into the cells 
[Dean et al., 2001; Sharom, 1997]. Therefore, tumors derived from these tissues have a 
greater expression of P-gp compared to others [Sharom, 2011]. The function, as well as the 
ATPase activity of the P-gp, seems to be affected by intra-cellular cholesterol levels since 
very high levels of cholesterol were found in the plasma membranes of MDR
+
 tumor cells 
[Gimpl et al., 1997; Kapse-Mistry et al., 2014; Ozben, 2006; Thomas and Coley, 2003; 
Troost et al., 2004]. In our previous works we demonstrated that nanocarriers loaded with 
Zol, an aminobisphosphonate clinically used to treat bone diseases, increase the in vitro 
antiproliferative effects of Doxo in Doxo-resistant cell lines; this effect was explained with 
the effect of Zol on the inhibition of the cholesterol production and, consequently, on the 
P-gp activity [Caraglia et al., 2010; Kopecka et al., 2015; Kopecka et al., 2016].  
Among the nanocarriers used as drug delivery systems, NPs based on PECs have attracted 
a great attention thanks to their low costs of manufacturing together with an easy scale-up 
and absence of organic solvents [Lankalapalli and Kolapalli, 2009; Patwekar et al., 2016]. 
In particular, ionotropic gelation process leads to spontaneous formation of PECs, as the 
result of electrostatic interactions between oppositely charged molecules. One of the main 
polymer suitable for gelation process is represented by CHI, a natural cationic 
polysaccharide composed of D-glucosamine and N-acetyl-D-glucosamine units, with well-
known biodegradability, biocompatibility and bioadhesiveness properties. In acidic 
environment, CHI positive charges makes it suitable for electrostatic interactions with an 
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anionic counterpart, such as tripolyphosphate (TPP) and/or HA [Fan et al, 2012; Gan et al., 
2005; Jonassen et al., 2012; Nasti et al., 2009;  Ramasamy et al., 2014]. The latter is an 
anionic biocompatible and non-immunogenic glycosaminoglycan, also with ability to bind 
CD44 and RHAMM receptors over-expressed in different cancer cells [Gotte and Yip, 
2006]. 
 
3.2 Aim of the work 
In this context, the aim of the present work was to develop PECs co-loading Doxo and Zol 
by ionotropic gelation process. The preparation conditions were optimized to achieve PECs 
with low mean diameter, narrow size distribution, stability during storage, and high 
Doxo/Zol encapsulation efficiency. Finally, in vitro studies were carried out on 
osteosarcoma (SAOS), Doxo-resistant osteosarcoma (SAOS DX) and breast cancer 
(MCF7) cell lines, to assess both the possibility of combined therapy to overcame 
resistance in Doxo-resistant tumor cells and the HA targeting ability. 
  
3.3 Materials and methods  
3.3.1 Materials 
CHI (molecular weight 300.000~500.000 Da, inherent viscosity: 200-400 mPa.s) and TPP 
were obtained from Sigma-Aldrich (USA). Poloxamer F127, a group of amphiphilic 
triblock polymer (number of oxyethylene units=100, number of oxyproptlene units=65) 
was purchased from Lutrol (Basf, Germany). HA (molecular weight ~ 180 kDa) was 
obtained from Contipro (Dolní Dobrouč, Czech Republic). Doxo hydrochloride from 3V 
Chimica (Rome, Italy), Zol monohydrate (1-Hydroxy-2-imidazol-1-ylethylidene) from 
U.S. Pharmacopeia Convention (Twinbrook Parkway, Rockville, USA) were used.  
 
3.3.2 Preparations of polyelectrolyte complexes (PECs)  
Uncoated blank PECs (PEC-CHI) were prepared by ionotropic gelation method. Briefly, 
CHI solution was prepared in 10 mL aqueous acetic acid (2% v/v); after complete 
solubilization the pH of the resulting solution was adjusted to 4.7 with NaOH (1N) and 
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filtrate trough 0.2 µm syringe filter. TPP solution was obtained by solubilizing TPP in 5 
mL of distilled water followed by filtration trough 0.2 µm syringe filter. Afterwards, PECs 
were obtained by adding the anionic solution into the CHI solution and lefting them under 
magnetic stirring (700 rpm, at room temperature) for 30 minutes, to allow the cross-linking 
reaction. The resulted PECs suspension was purified by centrifugation (two washing at 
10000 rpm, 10 min; Hettich Zentrifugen, Germany) and kept overnight at 4 °C. HA-coated 
PECs (PEC-HA) were prepared by using the same procedure described above for PEC-
CHI. However, for PEC-HA formulations, HA aqueous solution was added immediately 
after PEC-CHI purification. In particular, the supernatant obtained after PEC-CHI 
purification was discarded and replaced with the same volume of HA solution. The 
obtained suspensions was stirred at 1200 rpm for 15 min, to allow the electrostatic 
interactions between PEC-CHI and HA, and purified by centrifugation (5000 rpm, 5 min). 
Various CHI, TPP and HA concentrations, times of interaction between them, as well as 
surfactant addiction to the formulation were investigated. Loaded PEC (HA-coated and 
uncoated) were obtained by simply adding Doxo (0.1mg/mL) to CHI solution and Zol (0.2 
mg/mL) to TPP solution, prior to proceed with PEC preparation, forming: Zol loaded PEC 
(PEC-Zol); Doxo loaded PEC (PEC-Doxo); Zol and Doxo co-loaded PEC (PEC- Doxo-
Zol); HA-coated PEC Zol-loaded (PEC-Zol-HA); HA-coated PEC Doxo-loaded (PEC-
Doxo-HA); HA-coated PEC Zol and Doxo co-loaded (PEC- Doxo-Zol-HA). 
 
3.3.3 Size, polydispersity index and ζ potential 
The average diameters, polydispersity index (PI) and -potential of the obtained 
formulations were measured via dynamic light scattering (N5, Beckman Coulter, USA and 
Nano-Z, Malvern Instruments, UK). For the analysis, each PEC formulations were 
properly diluted with ultrapure water and measured at room temperature. Results were 
calculated as average of 5 runs of three independent samples. To evaluate PEC 
dimensional stability size and -potential measurements were monitored for at least 30 
days, in water at 4 °C (i.e. storage conditions). 
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3.3.4 Doxo and Zol encapsulation efficacy and preparation yield of the PECs 
PECs preparation yield was calculated from previously freeze-dried formulations (0.01 
atm, 24 hours; Modulyo, Edwards, UK). In particular, it was gravimetrically obtained from 
the entire mass of recovered freeze-dried PECs. For the entrapment efficiency (EE), the 
supernatant obtained after purification of loaded PECs (or the pellet for HA-coated PECs) 
containing free drugs, was submitted to quantitative analyses. In particular, the percentage 
of Doxo entrapped into PECs was evaluated by spectrophotometric assay (UV-1800, 
Shimadzu Laboratory World, Japan) at λ=480 nm. The linearity of the response was 
verified over the concentration range 62,5-0,06 µg/mL (r
2
> 0,99). Instead Zol 
encapsulation efficiency was measured by ultra-high-performance liquid chromatography 
(UHPLC, Shimadzu Nexera Liquid Chromatograph LC-30AD), performed on a Gemini 
C18, 110 Å column (250 mm × 4.6 mm, 5 µm) at a λ=220 nm, using a mobile phase 
composed of 20:80 (v/v) acetonitrile:tributyl-ammonium-phosphate buffer (pH=7). The 
flow rate was 1 mL/min and the run time was set at 15 min. The drugs encapsulation 
efficiency were calculated by the following equation: 
 𝐸𝐸 (%) =
Total amount of drugs in formulations−Free drugs 
Total amount of drugs in formulations 
x 100                                           
The values of the EE (%) were collected from three different batches. 
 
3.3.5 Cell culture 
SAOS, SAOS DX and MCF7 cell lines were obtained from American Type Culture 
Collection (ATCC; Rockville, MD). Wild type and SAOS DX cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM), while MCF7 were grown in Roswell Park 
Memorial Institute 1640 medium (RPMI). Both cell media were supplemented with 10% 
heat-inactivated fetal bovine serum, 20 mM HEPES, 100 U/mL penicillin, 100 mg/mL 
streptomycin, 1% L-glutamine and 1% sodium pyruvate. All the cells were cultured at a 
constant temperature of 37 °C in a humidified atmosphere of 5% carbon dioxide (CO2). 
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3.3.6 Cell proliferation assay 
After trypsinization, all the cell lines were plated in 100 L of medium in 96-well plates at 
a density of 2x10
3
 cells/well. One day later, the cells were treated with free Doxo, free Zol, 
PEC-CHI, PEC-HA, PEC-Doxo, PEC-Doxo-HA, PEC-Zol, PEC-Zol-HA, PEC-Doxo-Zol 
and PEC-Doxo-Zol-HA, at concentrations ranging from 20 µM to 0.156 µM for Doxo and 
from 200 µM to 0,312 µM for Zol. Cell proliferation was evaluated by MTT assay. 
Briefly, cells were seeded in serum-containing media in 96-well plates at the density of 
2×10
3
 cells/well. After 24 hours incubation at 37 °C, the medium was removed and 
replaced with fresh medium containing all developed formulations at different 
concentrations. Cells were incubated under these conditions for 72 hours. Then, cell 
viability was assessed by MTT assay. The MTT solution (5 mg/mL in phosphate-buffered 
saline) was added (20 μL/well), and the plates were incubated for further 4 hours at 37 °C. 
The MTT-formazan crystals were dissolved in 1N isopropanol/hydrochloric acid 10% 
solution. The absorbance values of the solution in each well were measured at 570 nm 
using a Bio-Rad 550 microplate reader (Bio-Rad Laboratories, Milan, Italy). Percentage of 
cell viability was calculated as described in the following equation: 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
(absorbance of the treated wells−absorbance of the blank control)
(absorbance of the negative control wells−absorbance of the blank control wells)
x 100  
Then, the concentrations inhibiting 50% of cell growth (IC50) were obtained and these 
values were used for subsequent experiments. MTT assay was carried out by triplicate 
determination on at least three separate experiments. All data are expressed as mean ± SD. 
 
3.4 Results and discussion 
3.4.1 Uncoated PEC preparations and characterization  
PEC based on CHI were firstly obtained through manual ionotropic gelation technique 
exploiting the ability of the amine functional groups of CHI to be protonated in acidic 
environment; the resulting -NH3
+
 groups are able to interact with negatively charged 
groups of TPP, leading to PEC formation [Janes et al., 2001]. Commonly, oppositely 
charged macromolecules aggregate due to their high charge density fluctuation in solutions 
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[Lankalapalli and Kolapalli, 2009]. Therefore, PECs formation and stability is affect by 
several factors [Masarudin et al., 2015]. Among these, CHI and TPP concentrations used 
during the preparation process play an important role. In table 3.1, the different polymer 
concentrations used, the size and PI of the different prepared PEC formulations are 
reported. In all the formulations, the volume ratios between CHI and TPP phases was fixed 
at 2:1.  
 
Formulation 
[CHI] 
mg/mL 
[TPP] 
mg/mL 
d (nm) IP 
PEC(CHI 0.4-TPP 0.5) 0.4 0.5 236.9±31.2 1.14±0.5 
PEC(CHI 0.3-TPP 0.5) 0.3 0.5 231.9±9.50 0.23±0.1 
PEC(CHI 0.5-TPP 0.4) 0.5 0.4 272.1±86.7 0.42±0.1 
PEC(CHI 0.5-TPP 0.3) 0.5 0.3 314.2±14.5 1.03±0.6 
PEC(CHI 0.5-TPP 0.5) 0.5 0.5 132.7±11.2 0.43±0.1 
PEC(CHI 0.4-TPP 0.4) 0.4 0.4 185.1±0.81 0.27±0.1 
PEC(CHI 0.3-TPP 0.3) 0.3 0.3 132.3±6.80 0.42±0.1 
PEC(CHI 0.3-TPP 0.5) 0.3 0.4 287.8±15.4 0.15±0.1 
Table 3.1: size and IP of different PEC formulations prepared using various CHI and TPP concentrations. 
All results are expressed as mean ± SD of at least three independent experiments 
 
Results showed that PECs with smallest size (in the range from ~ 130 to ~ 180 nm) were 
obtained using the same concentrations of both CHI and TPP. By increasing the TPP/CHI 
ratio, the PEC size significantly increased. This could be probably ascribed to the excess of 
TPP in solution; negative charges of TPP might interact with free amino groups of pre-
formed PECs, leading to a PEC aggregation. A similar size increase was observed by 
increasing CHI concentration. This effect was probably due to higher viscosity of the 
resulting solution, which slows down the cross-linking reaction between the polymers 
chains, with consequent formation of aggregates. Concentrations greater than 0.5 mg/mL 
of both components led to formation of visible macro-aggregates (data not shown). The 
time of interaction between CHI and the cross-linking agent was found to be another 
parameter influencing PEC size and PI. In particular, the optimal CHI and TPP 
concentrations, which led to the smallest PEC size, were used to prepare PECs with 
controlled-precipitation flow rate (Q). Results of dimensions, PI and ζ potential analysis of 
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PEC formulations, prepared by using different flow rate (Q = 500 and 133.3 L/min, 
named A and B respectively), are summarized in table 3.2. 
 
Formulation 
[CHI] 
mg/mL 
[TPP] 
mg/mL 
Q 
(µL/min) 
d 
(nm) 
PI 
 potential 
(mV) 
PEC(CHI 0.5-TPP 0.5)-A 0.5 0.5 500 223.3±3.8 0.67±0.3 18.1±1.5 
PEC(CHI 0.5-TPP 0.5)-B 0.5 0.5 133.3 187.0±9.1 0.45±0.2 21.3±1.1 
PEC(CHI 0.4-TPP 0.4)-A 0.4 0.4 500 147.7±2.9 0.49±0.1 19.1±1.9 
PEC(CHI 0.4-TPP 0.4)-B 0.4 0.4 133.3 129.4±2.7 0.42±2.7 19.1±0.8 
PEC(CHI 0.3-TPP 0.3)-A 0.3 0.3 500 127.5±2.2 0.51±0.3 17.8±2.9 
PEC(CHI 0.3-TPP 0.3)-B 0.3 0.3 133.3 104.4±1.4 0.41±0.3 21.4±1.9 
Table 3.2: size, PI and ζ potential values of different PEC formulations prepared using different CHI and 
TPP concentrations and different Q. In all formulations, the inner diameter of the syringe used for the 
precipitation of TPP into CHI solution was set at 11.99 mm. All results are expressed as mean ± SD of at 
least three independent experiments 
 
As it can be observed, PECs obtained using a lower flow rate showed smaller diameter. 
This size trend could be attributed to the time needed for the cross-linking reaction; thus, at 
lower flow rate, the possibility to achieve a homogeneous distribution of the polymer 
chains should be greater. This should promote their electrostatic interactions and formation 
of PECs with very small diameter (around ~ 100 nm). A positive charge, evaluated by  
potential analysis, was found in all the formulations due to the presence of CHI primary 
free amino groups. On the basis of these results, formulation PEC(CHI 0.3-TPP 0.3)-B, 
obtained by using a concentration of 0.3 mg/mL of both CHI and TPP and a flow rate of 
133.3 µL/min, resulted in the optimal features in terms of mean diameter, although with a 
high PI (~ 0.4) indicating a poor homogeneity of the PEC dispersion (table 3.2). Therefore, 
the poloxamer F127 at different concentrations was added to CHI acetic acid solution 
before PEC preparation [Hosseinzadeh et al., 2012]. As expected, the addition of F127 
resulted in significant IP reduction, depending on the poloxamer concentration. In 
particular, in the case of the PEC(CHI 0.3-TPP 0.3)-B, the addition of F127 at 10% (w/w) 
allowed to get more monodisperse PECs (IP < 0.25), without significant change in size and 
 potential value (table 3.3). 
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Formulation 
[CHI] 
mg/mL 
[TPP] 
mg/mL 
F127 
(% w/w) 
d 
(nm) 
PI 
 potential 
(mV) 
PEC(CHI 0.3-TPP 0.3)-B20 0.3 0.3 20 114.1±5.1 0.48±0.1 17.2±2.5 
PEC(CHI 0.3-TPP 0.3)-B16 0.3 0.3 16 114.8±6.9 0.32±0.2 16.9±2.1 
PEC(CHI 0.3-TPP 0.3)-B10 0.3 0.3 10 110.8±3.5 0.23±0.2 21.2±3.3 
Table 3.3: size, PI and ζ potential values of different PEC formulations prepared using different F127 
concentrations 
 
3.4.2 HA-coated PEC preparations and characterization  
The optimized uncoated PEC formulation PEC (CHI 0.3-TPP 0.3)-B10 (from here named 
PEC) was considered to develop HA-coated PECs. The negatively-charged HA can coat 
PECs surface by taking advantage of its ability to make electrostatic interactions with a 
cationic counterpart. A such approach should result easy to scale-up and avoid organic 
solvents and chemical reactions between polymers. The addition of different HA 
concentrations and time required for the interaction between anionic HA and cationic PEC, 
were investigated in order to achieve optimized formulations in terms of size. As shown in 
table 3.4, the HA addition resulted in a significant increase in PEC size.  
 
Formulation 
[HA] 
mg/mL 
Time of 
interaction 
(min) 
d (nm) PI 
 potential 
(mV) 
PEC-HA(0.3-15 min) 0.3 15 249.2±2.4 0.59±0.1 -17.1±1.1 
PEC-HA(0.3-30 min) 0.3 30 278.8±6.9 0.49±0.1 -12.6±1.2 
PEC-HA(0.6-15 min) 0.6 15 180.9±6.7 0.08±0.1 -23.1±1.2 
PEC-HA(0.6-30 min) 0.6 30 196.7±2.5 0.19±0.1 -26.8±1.3 
PEC-HA(0.9-15 min) 0.9 15 170.8±13 0.29±0.2 -20.1±0.9 
PEC-HA(0.9-30 min) 0.9 30 175.6±1.1 0.29±0.1 -16.5±1.5 
Table 3.4: size, PI and ζ potential values of different PEC-HA formulations prepared using different HA 
concentrations and times of interaction between HA solution and PEC formulations 
 
In particular, results showed that very homogeneous size distribution of PEC-HA (IP<0.1) 
was obtained when using a HA concentration of 0.6 mg/mL and a time of interaction of 15 
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min (PEC-HA(0.6-15 min)). Therefore, this formulation (from here named PEC-HA) was 
considered for the following step of the study. Furthermore, upon the addition of HA to the 
formulation, a switch in  potential value was observed from ~ +21 mV (PEC formulation) 
to ~ - 23 mV (PEC-HA formulation). The negative   potential was ascribed to the 
ionization of HA carboxyl groups, thus demonstrating the presence of the external HA 
moieties on PEC surface.  
 
3.4.3 Preparation and characterization of PEC encapsulating Doxo and Zol  
Doxo and Zol were loaded into PEC and PEC-HA formulations, to obtain a co-delivery of 
these drugs in a combined therapy. Doxo and Zol encapsulation efficiencies and 
preparation yield of different formulations are summarized in table 3.5.  
 
Formulation 
[Zol] mg/mL 
loaded 
[Doxo] mg/mL 
loaded 
E.E.  Zol   
(%) 
E.E. Doxo 
(%) 
Yield 
(%) 
PEC - - - - 80.8±0.1 
PEC-HA - - - - 92.5±0.4 
PEC-Zol 0.2 - 55.1±1.8 - 77.8±1.3 
PEC-Zol-HA 0.2 - 53.6±5.6 - 96.5±0.4 
PEC-Doxo - 0.1 - 37.7±9.4 79.4±0.1 
PEC-Doxo-HA - 0.1 - 29.1±7.7 80.9±0.1 
PEC-Zol-Doxo 0.2 0.1 58.7±1.6 37.6±3.9 81.6±0.1 
PEC-Zol-Doxo-HA 0.2 0.1 52.9±3.3 31.3±3.1 83.3±0.1 
Table 3.5: Doxo and Zol encapsulation efficiency (%) and yield (%) of different formulations prepared. In all 
cases CHI (0.3 mg/mL), TPP (0.3 mg/mL) and HA (0.6 mg/mL) were used 
 
As shown, the prepared formulations were characterized by a high yield, greater than 70% 
in all cases. Zol and Doxo encapsulation efficiency was found to be similar in PECs loaded 
with one or both drugs. Furthermore, the presence of HA into the formulation did not seem 
to significantly affect the percentage of drugs loaded into the PECs. The mean size, as well 
as the PI of PECs loaded with one or both drugs, resulted slightly increased. On the other 
hand, the two molecules did not affect the behaviors of PEC-HA, which showed a diameter 
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of about 170 nm with a polydispersity index of ~ 0.1 (table 3.6). As it can be observed in 
table 3.6, when HA was added to the formulations, potential of the formulations shifted 
from positive to negative values. 
 
Formulation d (nm) PI 
 potential 
(mV) 
PEC-Zol 131.1±0.1 0.32±0.1 20.2±1.3 
PEC-Zol-HA 180.9±1.4 0.18±0.2 -18.6±0.3 
PEC-Doxo 120.5±4.7 0.42±0.4 22.9±1.6 
PEC-Doxo-HA 173.7±9.7 0.11±0.1 -22.1±0.4 
PEC-Zol-Doxo 111.5±0.1 0.39±0.4 23.1±2.3 
PEC-Zol-Doxo-HA 176.5±1.2 0.12±0.1 -18.8±0.5 
Table 3.6: size, PI and ζ potential of different loaded PEC formulations 
 
3.4.4 Stability studies 
In order to evaluate the stability of prepared formulations, mean diameters, PI and -
potential were analyzed up to 30 days of storage in water at 4 °C. As shown in figure 3.1, 
PECs coated with HA had a narrow size distribution than PECs without HA. This 
suggesting that HA could act as stabilizer presumably conferring high density of negative 
charges on the PEC surface and/or due to a "steric clamping" effect of HA on the PEC 
surface. For all analyzed formulations potential values resulted stable up to 30 days, thus 
suggesting the permanence of HA on PEC surface (data not shown).  
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Figure 3.1: size and PI of different PECs formulations, at 0 time and after 30 days in water at 4 °C 
 
3.4.5 Cell proliferation assay  
The effects of free Doxo, free Zol, PEC, PEC-HA, PEC-Doxo, PEC-Doxo-HA, PEC-Zol, 
PEC-Zol-HA, PEC-Doxo-Zol and PEC-Doxo-Zol-HA, were evaluated on the proliferation 
of wild type SAOS, SAOS DX and MCF7 cancer cell lines by MTT assay. All the tested 
formulations induced a dose-dependent growth inhibition in all the cell lines analyzed after 
72 hours, while treatment with blank PEC did not produce significant cytotoxic effects 
(figure 3.2). 
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Figure 3.2: effect of all developed formulations on wild type and doxo–resistant SAOS and MCF 
proliferation 
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In table 3.7, results are reported as concentrations inhibiting 50% of cell growth (IC50) 
after 72 hours of treatment.  
 
    
SAOS IC50
Doxo 2
PEC-Doxo 0.5
PEC-Doxo-HA 0.4
PEC-Doxo-Zol 0.05
PEC-Doxo-Zol-HA 0.2
PEC -
PEC-HA -
SAOS DX IC50
Doxo >20
PEC-Doxo 10.04
PEC-Doxo-HA 12.29
PEC-Doxo-Zol 0.9462
PEC-Doxo-Zol-HA 6.456
PEC -
PEC-HA -
SAOS DX IC50
Zol 23.41
PEC-Zol >200
PEC-Zol-HA >200
PEC-Doxo-Zol 13.84
PEC-Dox-Zol-HA 98.19
PEC -
PEC-HA -
MCF 7 IC50
Zol 6.2
PEC-Zol 14
PEC-Zol-HA 90
PEC-Doxo-Zol <0.3
PEC-Doxo-Zol-HA 1
PEC -
PEC-HA -
MCF-7 IC50
Doxo 18
PEC-Doxo 0.12
PEC-Doxo-HA 0.09
PEC-Doxo-Zol < 0.019
PEC-Doxo-Zol-HA 0.07
PEC -
PEC-HA -
SAOS IC50
Zol 17
PEC-Zol 16
PEC-Zol-HA 108
PEC-Doxo-Zol 0.8
PEC-Doxo-Zol-HA 2.7
PEC -
PEC-HA -
 
Table 3.7: IC50 of all developed formulations on wild type, Doxo–resistant SAOS and MCF, after 72 
hours of treatment 
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In details, IC50s of free Doxo were equal to 2M for wild type SAOS, superior to 20M 
for SAOS DX and equal to 18 M for MCF7. The Doxo encapsulated in PEC (PEC-
Doxo) induced a 50% growth inhibition at a concentration of 0.5, 10 and 0.12 M in 
wild type, SAOS DX and MCF7, respectively (table 3.7). These data demonstrated that 
PECs, also without the co-encapsulation of Zol, are able to strongly increase the 
cytotoxicity of Doxo. It is worthy of note that Doxo encapsulation in other nanocarriers, 
e.g. stealth liposomes, results in a reduced Doxo cytotoxicity [Alberts and Garcia, 1997; 
Gabizon and Martin, 1997; Working et al., 1999]. In the case of PEC, it is possible to 
hypothesize an enhanced uptake into the cells and consequent higher Doxo intracellular 
delivery. On the other hand, the PEGylated nanocarriers have been shown to reduce the 
drug uptake into the target cells [Verhoef and Anchordoquy, 2013]. IC50s of free ZOL 
were equal to 17M in wild type SAOS, 23 M in SAOS DX and 6.2 M in MCF7. 
The encapsulation of ZOL in PECs did not potentiate its antitumor activity, in fact IC50 
for PEC-Zol values were 16, >200 and 14 for wild type, SAOS DX and MCF7, 
respectively. These results are in contrast with our previous finding in which different 
lipid-based nanocarriers encapsulating Zol were useful to increase Zol uptake in 
different cancer cell lines [Marra et al., 2011; Salzano et al., 2011]. Here, when 
incubating wild type SAOS and MCF-7 with PEC-Zol only a citotoxicity similar or 
slightly higher, compared to naked Zol, was found. Thus, the strong interaction between 
CHI and Zol could slow the delivery of the bisphosphonate into the cytoplasm. Further 
studies are needed to understand the disappearance of Zol toxicity when incubating 
SAOX DX with PEC-Zol. On the other hand, PEC-Doxo-Zol inhibited the 50% of cell 
growth at a concentration of 0.05, 0.9 and 0.019 M for Doxo and 0.8 13 and <0.3M 
for Zol on wild type, SAOS DX and MCF7, respectively, by enhancing significantly the 
effects of both the drugs. The functionalization of PECs with HA resulted in different 
effect depending on the type of cancer cells. In particular, PEC-Doxo-HA induced a 
50% growth inhibition at a concentration of 0.4, 12 and 0.09 M in wild type, SAOS 
DX and MCF7, respectively. IC50s of PEC-Zol-HA were equal to 108 M for wild type 
SAOS, superior to 200 M for Doxo-resistant SAOS and equal to 90 M for MCF7. On 
the other hand, PEC-Doxo-Zol-HA inhibited 50% of cell growth at a concentration of 
0.2, 6.4 and 0.07 M for Doxo and 2.7, 98 and 1 M for Zol on wild type, SAOS DX 
and MCF7, respectively. As summarized in table 3.7, a synergic effect was found when 
co-encapsulating Doxo with Zol. Interestingly, the data on SAOX DX strongly confirm 
69 
 
our previous finding on the association of Doxo and Zol to revert resistance to Doxo 
[Kopecka et al., 2016]. In particular, it has been hypothesized that Zol is able to restore 
the sensitivity in Doxo resistant cancer cells by acting on the mevalonate pathway, 
reducing P-gp expression and thus re-inducing the direct Doxo cytotoxicity. Here, in 
addition, a synergic effect was also found in wild type cells, thus suggesting that other 
mechanism different than the inhibition of the P-gp could arrive when associating these 
two drugs. On the other hand, the functionalization of PECs with HA potentiated the 
antitumor efficacy of Doxo but not the cytotoxicity of Zol. Indeed, PEC-Doxo-Zol-HA 
was more potent than free Doxo and Zol but not than PEC-Doxo-Zol, this effect was 
more evident in MCF7 that overexpressed CD44 receptor. This could be probably 
ascribed to the saturable cells receptor effect, on which the HA-uptake mechanism is 
based [Ouasti et al., 2012]. After administration into the body, free HA in solution could 
compete with PEC-HA to bind the same receptors expressed on cells surface. HA-CD44 
interaction cause receptor internalization and consequently degradation by cellular 
enzymes; afterwards, CD44 expression takes about 24-48 hours. During this time frame, 
only a limited number of receptors will be available to cluster around HA-coated PEC, 
thus resulting in significantly decrease of receptor-mediated endocytosis of PEC-HA in 
CD44 overexpressing cancer cells [Almalik et al., 2013].  
 
3.5 Conclusions 
In the present study, CHI/TPP/HA based-PECs co-loaded with Doxo and Zol were 
successfully prepared with a simple and easily up-scalable method. Some parameters 
such as polymer concentration, times of interaction between them and surfactant 
addiction to the formulations were found to be crucial for PEC formation and 
technological features. The presence of HA moieties on PEC surface increases their 
stability over time. PEC co-delivery of Doxo and Zol enhances Doxo delivery in Doxo-
resistant cell lines, thus providing a promising approach to overcome MDR. Differently 
to what was expected, despite HA-coated PECs are able to increase the cytotoxicity 
compared to free drugs, they were no more potent compared with uncoated PEC-Doxo-
Zol, also in MCF7 cell lines overexpressing CD44 receptor. Additional studies will be 
done to confirm this effect and to evaluate the in vivo pharmacokinetics of the carriers.   
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CHAPTER 4  
Spontaneous arrangement of a tumor targeting hyaluronic acid shell on 
irinotecan loaded PLGA nanoparticles 
 
ABSTRACT 
The arrangement of tumor targeting HA moieties on irinotecan (IRIN)-loaded PLGA NPs 
has been directed by means of a gradient of lipophilicity between the oil and water phases 
of the emulsion used to produce the NPs. PLGA constitutes the NP bulk while HA is 
superficially exposed, with amphiphilic poloxamers acting as a bridge between PLGA and 
HA. Differential scanning calorimetry, zeta potential analyses and ELISA tests were 
employed to support the hypothesis of polymer assembly in NP formulations. The presence 
of flexible HA chains on NP surface enhances NP size stability over time due to an 
increased electrostatic repulsion between NPs and a higher degree of hydration of the 
device surface. IRIN in vitro release kinetics can be sustained up to 7–13 days. In vitro 
biologic studies indicated that HA-containing NPs were more toxic than bare PLGA NPs 
against CD44-overexpressing breast carcinoma cells, therefore indicating their ability to 
target CD44 receptor. 
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4.1 Introduction 
New cancer therapies based on polymeric NPs have attracted great deal of interest due to 
their ability to encapsulate a wide array of anticancer drugs and to control their release at 
tumor target site [Brigger et al., 2002; Cho et al., 2008]. Among the materials used to 
produce polymeric NPs, PLGA play a dominant role [Athanasiou et al., 1996; Jain, 2000]. 
It is a synthetic copolymer of lactic acid (hydrophobic portion) and glycolic acid 
(hydrophilic portion), approved from FDA for clinical applications, thanks to its 
biocompatibility, non-toxicity and total in vivo biodegradability [Jalil and Nixon, 1990]. 
Bioerosion causes the chemical degradation by forming low molecular weight water-
soluble derivatives, which are then eliminated through the typical metabolic processes of 
the body. NPs can increase the drug concentration in cancer cells and help overcoming the 
limitations of conventional chemotherapy, which lacks specificity and elicits severe toxic 
effects toward healthy cells [Ricci and Zong, 2006]. As already mentioned in the first 
chapter (paragraph 1.5), one known strategy to promote NPs accumulation into tumor cells 
and tissues relies on passive targeting, taking advantage of the EPR effect [Bae et al., 
2011; Wang et al., 2005]. It must be underlined that size, surface-charge and 
hydrophobicity of NPs in which the drug is loaded strongly affect the drug bioavailability. 
In previous work we exploited the possibility to formulate PLGA NPs coated with 
hydrophilic poly (ethylene oxide) (PEO) moieties without a chemical reaction between the 
two polymers, therefore avoiding the presence of chemical reaction solvents and wastes 
[Mayol et al., 2015]. This helps overcoming the above mentioned tolerability/approval 
issues and representing an obvious advantage from a formulative point of view. Indeed, 
taking advantage of the amphiphilic properties of the blends, a hydrophilic coating of the 
NPs can spontaneously form, thus endowing NPs with a higher dimensional stability and 
the ability to take advantage of EPR effect. However, the effectiveness of the drug 
bioavailability can be probably enhanced when NPs uptake is optimized. In particular, NP 
internalization faces a size threshold limitation and, for this reason, in another study we 
have explored the nanoprecipitation technique with the aim to obtain NPs smaller in size 
and narrower in size distribution, and thus more suitable for cell uptake [Serri et al., 2017]. 
In this study we verified that an efficient uptake of NPs in malignant mesothelioma cell 
line (MSTO-211H) is strongly affected by size and polydispesity index of the developed 
nanodevices. Actually, uptake data indicate that a size reduction of only 20 nm leads to an 
evident increase in NP internalization. In this scenario, nanoprecipitation method was 
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found to improve the control of NP size and size distribution that, in turns, enhances cell 
internalization as showed in MSTO-211H. The uptake experiments clearly showed a 
cytoplasmic regionalization of the NPs and a rapid internalization increasing over the time. 
Actually, an optimization of NP uptake can significantly affect the biological efficacy of 
the platform/payload. Therefore, the identification of a clear subcellular localization may 
also indicate the feasibility of the formulation. 
Even if EPR does enhance some drug accumulation at tumor target sites through the 
preferential extravasation of long-circulating devices, its efficacy is limited to a few 
percent of the administered dose and is associated to a possible lack of NPs cell 
internalization and/or to the undesired release of the loaded drugs before NPs uptake [Bae 
et al., 2011; Choi et al., 2010]. To overcome these issues, a significant research effort is 
devoted to endow NPs with biomolecular active targeting through suitable modifications of 
device surface. Functionalized NPs can recognize and bind tumor cells, and can also be 
internalized by receptor-mediated endocytosis [Byrne et al., 2008; Peer et al., 2007; 
Torchilin, 2006]. In this frame, the polysaccharide HA has attracted significant research 
attention for tumor-targeted delivery since it is biocompatible and non-immunogenic, and 
can specifically bind CD44 and RHAMM receptors, which are overexpressed in many key 
forms of cancer [Ossipov, 2010; Choi et al., 2010; Toole, 2004 ]. Several HA-based drug 
carriers have been studied for tumor targeting. Since HA has multiple functional groups 
available for chemical conjugation, several HA-drug conjugates have been developed as 
macromolecular prodrugs [Auzenne et al., 2007; Pouyani and Prestwich, 1994]. HA has 
also been chemically anchored onto manifold drug-loaded NPs; moreover, amphiphilic HA 
derivatives have been synthesized by chemically grafting several hydrophobic moieties so 
as to produce HA-based micellar systems for the release of hydrophobic chemotherapeutic 
drugs [Borzacchiello et al., 2007; Choi et al., 2011; Lee et al., 2009; Mayol et al., 2014; 
Yadav et al., 2010]. These HA modified macromolecular prodrugs and nano-sized drug 
carriers exhibited enhanced tumor targeting ability and therapeutic efficacy, compared to 
free anticancer agents [Nishiyama, 2007]. However, HA-modified macromolecular 
prodrugs and nano-sized drug carriers have been obtained by means of a chemical reaction, 
which is likely to alter HA biological properties. Besides, the preparation of HA NPs by a 
chemical reaction is still facing regulatory and technological challenges such as the 
absence of FDA approval and the limited upscalability of the process. It must be 
underlined that HA-coated solid lipid NPs which do not involve a chemical reaction have 
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been recently developed. Unfortunately, despite the promising results, the control of drug 
delivery kinetics is less than satisfactory and the delivery of the drug payload is most likely 
to occur before NPs reach the tumor site [Tran et al., 2014]. In this panorama, NPs 
produced by Layer-by-Layer (LbL) technology are an emerging class of self-assembled 
polymeric drug carrier that addresses several challenges in the delivery of small molecule 
therapeutics and imaging agents [Dreaden et al., 2014]. With this approach, an 
electrostatically driven self-assembly of oppositely charged polymers allows the 
functionalization of NP surface with HA. Different methods to directed the self-assembly 
of tumor targeting HA moieties with an easily upscalable method, could be a promising 
alternative to LbL thecnology. 
 
4.2 Aim of the work 
In this work, a novel and simple method based on single emulsion technique to produce NP 
has been proposed. This technique is based on the self-aggregation of polymers driven by a 
lipophilicity gradient between the oil and water phases of the emulsion, thus allowing the 
simultaneous NP formation and coating with HA in a single step, differently from LbL. 
Here IRIN-loaded biodegradable PLGA NPs have been formulated and coated with non-
chemically modified HA for tumor targeting toward CD44-overexpressing cell lines. IRIN 
is a topoisomerase I inhibitor which causes DNA strand breakage and widely employed in 
chemotherapy, also in combination with Doxo [Biondi et al., 2013a; Biondi et al., 2013b]. 
Besides topotecan, IRIN is the only topoisomerase I-targeted anticancer drug and its 
efficacy is strongly limited since a chemical equilibrium between the lactone form and the 
ring-opened form exists in solution [Teicher, 2008]. The ring-opened carboxylate form is 
90% less effective than the lactone form and its cell membrane crossing is hampered 
[Hertzberg et al., 1989]. Therefore, the administration of IRIN suspended within a 
nanodevice able to cross the cell membrane may be promising to overcome these issues. 
Furthermore, an active targeting to tumor cells and tissues is helpful to reduce the side 
effects associated to the IRIN interaction with non-target tissues and organs. The stability 
of the formulated IRIN-loaded NPs was evaluated by measuring their size over time and in 
vitro drug release studies have been taken to evaluate the capacity of the produced NPs to 
control and prolong IRIN release. Differential scanning calorimetry (DSC), potential 
analyses and ELISA tests were employed to investigate polymer assembly in NP 
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formulations. Finally, in vitro biological test on both cells overexpressing and not 
overexpressing CD44 receptor, respectively human breast carcinoma cells (HS578T) and 
L-929 cells, were performed to assess NP toxicity and targeting ability to CD44 receptor. 
 
4.3 Materials and methods 
4.3.1 Materials 
HA with a weight-average molecular weight (MW) of 850,000 Da was provided by 
Novozymes Biopharma (Denmark). Equimolar PLGA (RG504H, MW 12,000 Da) was 
purchased from Boheringer Ingelheim (Germany). Poloxamers (PEOa-PPOb-PEOa) F127 
(a = 100 and b = 65) and F68 (a = 76 and b = 29), obtained from Lutrol (Basf, Germany), 
were used. IRIN, acetone and dimethyl sulfoxide (DMSO) were obtained from Sigma–
Aldrich (USA). Phosphate buffer saline (PBS) tablets without calcium and magnesium 
were obtained from MP Biomedicals Inc. (France). 
 
4.3.2 NPs preparation 
Blank and IRIN-loaded NPs were prepared by a single emulsion-solvent evaporation 
technique (oil in water). Formulations with different amounts of HA, PLGA and 
poloxamers are summarized in table 4.1. 
 
Table 4.1: composition and acronyms of the different NP formulations; all concentrations are expressed as % 
(w/w) 
 
Acronym OIL PHASE (O) WATER PHASE (W1) 
 PLGA F68 F127 HA F68 F127 
P 2 - - - 0.05 0.05 
PP 1 0.5 0.5 - 0.05 0.05 
PPHA30 1 0.5 0.5 2 0.05 0.05 
PPHA60 1 1.5 1.5 4 0.05 0.05 
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Briefly, 1 mL of PLGA solutions in acetone alone or blended with polox (F127 and F68 
1:1 w/w) were prepared with a PLGA-polox weight ratio fixed at 1:1 and an overall 
polymer concentration of 2% w/v. The organic phase was emulsified by sonication using a 
Branson Ultrasonic Cleaners (Model 3510) for 5 min with 40 mL of water phase, possibly 
containing different HA and polox amounts, as schematically represented in figure 4.1. 
More in detail, for HA containing NPs, two water phases were prepared (W1 and W2) and 
consecutively added; W1 phase contained different amounts of HA and polox in 15 mL, 
were emulsified with oil phase by sonication then W2 phase containing pure bidistilled 
water (25 mL) was added, to enhance the separation of the nanodroplets. The resulting 
emulsion was evaporated at 35 °C for 35 minutes by means of a rotary evaporator 
(Laborota 4010 digital, HEIDOLPH). NPs were finally separated from supernatant by 
centrifugation at 13000 rpm for 60 minutes (Hettich Zentrifugen, Germany) and stored at -
80 °C. As regards to the IRIN-loaded NPs, IRIN (10 mg) were added in the oil phase at a 
polymer concentration of 2%. 
 
 
Figure 4.1: schematic representation of NPs preparation 
 
4.3.3 NP characterization: morphology, mean size, size distribution and ζ potential 
NPs morphology was investigated through a transmission electron microscope (TEM, FEI 
Tecnai G12 Spirit Twin) with emission source LaB6 (120 kV, spotsize 1) using 400 mesh 
carbon-coated copper grids at room temperature. The carbon-coated copper grid was 
immersed in ultradiluted NP suspension and, after the drying phase, the grid was placed on 
a rod holder for the TEM characterization. Three grids per NP suspension were prepared 
and a minimum of four micrographs per grid were acquired. Surface topography and phase 
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signals of NPs were recorded by atomic force microscopy (AFM, NanoWizard II-AFM, 
standalone top View Optics, JPK Instruments, Germany) by placing one drop of NP 
suspension (1 mg/mL) on a freshly cleaved mica surface. For AFM observations, the 
suspension was air-dried at room temperature. Particle size and ζ potentials of NPs were 
determined via dynamic light scattering (DLS) measurements with a Zetasizer Nano 
(Malvern Instruments, Malvern, UK). For particle size measurements, NPs were suspended 
in ultrapure water. To study the agglomeration dynamics of NPs in bidistilled water at 4 
°C, NPs size measurements were taken for ten days. Furthermore, ζ potential assay was 
performed at different pH values (from 7.4 to 2) at room temperature. Results were 
averaged on at least five measurements. 
 
4.3.4 Thermal analyses  
Aiming to study the interactions between the different polymers in NP formulation, 
thermoanalytical tests were carried out on PLGA and poloxamer powders, along with 
freeze-dried P, PP and PPHA NPs, to study the interactions between the different polymers 
in NP formulation. The heat involved in the phase transitions of polymers was determined 
by a differential scanning calorimeter (DSC; DSC Q20, TA Instruments, U.S.A.), 
calibrated with a pure indium standard. The samples were placed in aluminum pans and 
underwent a double scan; the first was carried out from 10 to 80 °C to eliminate the 
thermal history of the samples and the second one from -60 °C to 80 °C. Heating rate was 
set at 5 °C/min. Measurements were carried out under an inert nitrogen atmosphere, purged 
at a flow rate of 50.0 mL/min. The heat evolved during polymer crystallization and fusion 
(W/g) was calculated from the recorded DSC thermograms by integrating the 
exothermic/endothermic peaks, while the glass transition temperature (Tg) was obtained 
from thermogram inflection point.  
 
4.3.5 Drug entrapment efficiency 
Drug entrapment efficiency (EE) was calculated by dissolving freeze-dried NPs (1 mg) in 
1 mL of DMSO. The resulting solution was sonicated for 1 hour in a water bath at 59 kHz, 
100% power. IRIN content was quantified by spectrophotometric assay (UV-1800, UV-
VIS spectrophotometer, Shimadzu, Japan) at 370 nm. The linearity of the response was 
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verified on IRIN solutions in DMSO (0.04–10 µg/mL concentration range; r2>0.99). 
Entrapped IRIN percentage was calculated as  
T
E
D
D
XEE 100   
where DE is the amount of entrapped drug in the NPs and DT is the total amount of the drug 
used to prepare the NPs. Results were averaged on at least three independent batches. 
 
4.3.6 In vitro release kinetic of IRIN 
For release experiments, NPs were suspended in 10 mL of release medium (PBS at pH 7.4) 
and incubated at 37 °C in an orbital incubator (SI50, Stuart R, UK) operating at 100 rpm. 
At scheduled time intervals, 1 mL aliquots were withdrawn and replaced with the same 
volume of fresh medium. The aliquots were ultracentrifuged and the supernatant was 
analyzed through spectrophotometric analysis (λ=364.5 nm) to quantify IRIN content. The 
instrument response was linear over the concentration range 0.1–50 μg/mL (r2>0.99). The 
experiments were run in triplicate.  
 
4.3.7 Quantification of HA  
The amounts of HA incorporated in/on the NPs were quantified as reported elsewhere 
[Mondalek et al., 2010]. Briefly, HA was determined after conjugation with a specific 
enzyme provided by a HA ELISA kit (Biorbyt LLC, USA), followed by 
spectrophotometric analysis at 450 nm after each washing step. More in detail, the amount 
of HA incorporated in the NP was determined by subtracting, from the initial mass of HA, 
the amount lost in the three NP washes. The linearity of the kit response was assessed in 
the 0–250 ng/mL HA concentration range (r2 > 0.96). 
 
4.3.8 Cell culture studies 
L929 cells originating from Mouse C34/An connective tissue were obtained from the 
European Collection of cell cultures (Sigma-Aldrich, USA) and were used at a passage 15-
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23. CD44-overexpressing human breast carcinoma HS578T cells, kindly gifted by Dr. 
Olga Zeni (IREA-CNR), were used. The cells were grown at 37 °C and 5% CO2 in T-75 
cell culture ﬂask (Falcon, Italy), using DMEM (Hyclone, USA) cell culture medium 
supplemented with 10% fetal bovine serum and antibiotics (penicillin G sodium 100 
U/mL, streptomycin 100 µg/mL). In the case of HS578T cells, the culture medium was 
enriched with 10 µl/mL bovine insulin. When conﬂuent growth was reached, the cells were 
detached with 0.25% trypsin-EDTA solution and washed twice with fresh PBS. The 
resulting cell suspensions were centrifuged for 5 min at 10000 rpm (BRK55/10 Centrifuge, 
Centurion Scientific Ltd, UK). Finally, the supernatant was separated and the cells 
resuspended in fresh culture medium. Viable cells were counted using the TC20 automated 
cell counter (Biorad, USA). 
 
4.3.9 In vitro cytotoxicity 
L929 and HS578T cells were seeded in 48-well plates at a density of 5 x 10
3
 cells per well 
in the presence of 200 µL of cell culture medium. Five wells were used as blank control. 
To determine the 50% inhibitory concentration (IC50) of the drug, the cells were exposed 
at IRIN solutions at concentrations ranging from 10 to 230 µM. In particular, after 24 
hours incubation at 37 °C in 5% CO2 atmosphere, the incubation medium was removed 
and 200 µL of IRIN solution at the same concentration was added. Afterwards, the cells 
were incubated for 48 hours and their viability assessed by alamar blue test. The 
biocompatibility of void PP and PPHA30 NPs as well as the bio-efficacy of IRIN loaded 
PP and PPHA30 NPs were estimated using an amount of NPs equivalent to that used to 
load an IRIN dose correspondent to IRIN IC50. Both L929 and HS578T cells were 
incubated with the tested NPs for 48 hours, and their viability was assessed by alamar blue 
test. HS578T cells, after the test, were rinsed and an amount of NPs equivalent to IRIN 
IC50 was added; the cells were then incubated for further 72 hours and their viability 
assessed by alamar blue test.  
Alamar blue test was performed by adding the alamar blue (AB) reagent to the samples (at 
10% v/v with respect to the medium) and incubated at 37 °C for 4 hours. The absorbance 
of the samples was measured using a spectrophotometer plate reader (Multilabel Counter, 
1420 Victor, Perkin Elmer) at 570 nm and 600 nm. AB is an indicator dye that incorporates 
an oxidation-reduction indicator whose color changes in response to the chemical 
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reduction in growth medium resulting from cell viability. Data are calculated as the 
percentage difference between treated and control samples with the following formula: 
   
   
100%
2112
2112 



POPO
AOAO
reduction  
where O1 is the molar extinction coefficient (E) of oxidized AB at 570 nm; O2 is the E of 
oxidized AB at 600 nm; A1 is the absorbance of test wells at 570 nm; A2 is the absorbance 
of test wells at 600 nm; P1 is the absorbance of positive growth control well at 570 nm; P2 
is the absorbance of positive growth control well at 600 nm. 
 
4.3.10 Statistical analyses 
In all cases, quantitative data are reported as mean value ± standard deviation (SD). The 
statistical significance of the results has been assessed by one-way analysis of variance 
ANOVA. An p value < 0.05 was considered to identify statistically different groups.  
 
4.4 Results and discussion 
4.4.1 NPs preparation and characterization  
In recent years, many ‘smart’ nanosystems for targeted cancer therapy have been 
developed, in order to increase the safety of use and the effectiveness of the loaded 
chemotherapy drugs [Cho et al., 2008; Brigger et al., 2002; Huang et al., 2013; Ding et al., 
2012]. Furthermore, it is also desirable to endow the produced devices with targeting 
ability toward cancer cells. A convenient way of developing such NPs can exploit their 
spontaneous assembly in emulsion, driven by a lipophicity gradient between the core and 
the external surface of the NPs, which forms core-shell NPs in aqueous environment. Here, 
we have developed a one-step procedure to obtain amphiphilic PLGA-based NPs decorated 
with an external HA corona, in which hydrophilic HA was combined to hydrophobic 
PLGA via amphiphilic poloxamer bridging. In particular, HA is the hydrophilic domain of 
NPs and therefore would arrange on the outer shell of the devices, while hydrophobic 
PLGA would form the core of the NPs, as schematically represented in figure 4.2. These 
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nanosystems have been engineered to combine device stability and targeting ability to 
CD44-overexpressing cancer cells. 
 
 
Figure 4.2: schematic representation of the NPs characterized by HA shell, biodegradable PLGA-core and 
poloxamers that act as bridge between PLGA and HA 
 
HA-decorated NPs have been formulated by dissolving PLGA and poloxamers in acetone 
and by emulsifying the obtained solution in an aqueous phase containing HA and, in case, 
poloxamers. The overall polymer concentration (PLGA and poloxamers) in the oil phase 
has been fixed at 2% w/v, while different amounts of HA and poloxamers in the external 
aqueous phase have been added. HA is known to be a strong polyanion at physiological pH 
and, therefore, the robustness of HA self-assembly on NP surface can be monitored by ζ 
potential analyses.  
Results of size and ζ potential measurements are summarized in table 4.2 and shown that 
NPs size is progressively increasing with increasing HA concentration in the external 
aqueous phase, while ζ potential values significantly decrease from ~ -27mV of PP to ~ -57 
mV for PPHA60.  
 
 
 
 
HA shell 
Biodegradable  
core 
Poloxamers 
PEO-PPO-PEO 
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Forms PDIt=0 d(nm) t=0 d(nm) t=10 d 
 potential 
(mV) t=0 
 potential 
(mV) t=10 d 
P 0.156 ± 0.01 154 ± 2.0 190 ± 10 -15.0 ± 0.8 -26.1 ± 1.7 
PP 0.082 ± 0.01 106 ± 1.1 110 ± 10 -25.5 ± 1.2 -29.1 ± 1.8 
PPHA30 0.884 ± 0.01 184 ± 4.3 161 ± 20 -49.7 ± 1.4 -49.3 ± 0.9 
PPHA60 1.230 ± 0.01 306 ± 14 258 ± 14 -56.2 ± 1.0 -57.0 ± 2.1 
Table 4.2: NP size and zeta potential at time zero and after 10 days in bidistilled water at 4°C. The mean 
values and standard deviations were calculated from at last three independent experiments 
 
These results indicate the formation of an external HA shell, driven by a lipophilicity 
gradient between the oil and water phases of the emulsion used to produce the NPs. A ζ 
potential value equal to -50 mV is more negative than the one observed in the case of NPs 
coated by HA, prepared through LbL procedure, thus suggesting a more uniform and 
efficacious cover of the polysaccharide on NP surface with the novel production method 
presented in this work [Dreaden et al., 2014]. A negative zeta potential, which is due to the 
ionization of the carboxyl groups of HA, can prevent NP aggregation and binding to 
plasma proteins, therefore promoting their stability and prolonged circulation in vivo. 
Furthermore, the ζ potential of NPs was found to be increasing with decreasing pH and, in 
particular, a quasi-neutral surface charge was found in the case of PPHA NPs, at a pH 
close to HA pKa (pH ~ 2), due to the protonation of the carboxyl groups on HA under 
decreasing pH (figure 4.3) [Huang et al., 2014]. Differently, HA-free NPs neutralize their 
superficial charge at the pKa of PLGA (pH ~  4) [Yoo and Mitragotri, 2010]. 
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Figure 4.3: zeta potential values of different NP formulations as a function of pH. The mean values and 
standard deviations were calculated from at last three independent experiments 
 
The presence of 0.2 % w/v of poloxamers in the external aqueous phase allows to obtain 
NPs with a lower mean diameter, without affecting the zeta potential value. This can be 
reasonably ascribed to the ‘bridging’ action of poloxamers between the inner hydrophobic 
PLGA and the outer hydrophilic HA domains. Indeed, it can be easily hypothesized that 
the surfactant properties of poloxamers help creating a less steep gradient of lipophilicity, 
which encourages the interaction and arrangement of HA chains on the surface of PLGA 
NPs.  
In the clinical administration of NPs, the phenomenon of particle aggregation represents, of 
course, a crucial issue, affecting the drug release profile and possibly increasing the risk of 
vessel occlusion. For these reasons, the electrostatic and/or steric stabilization of NPs is an 
important aspect to be considered. In table 4.2, the results of NP dimensional stability 
experiments are reported. These findings point that a tumor-targeting HA corona enhances 
NP dimensional stability over time thanks to the higher electrostatic repulsion of PPHA 
NPs which, in turn, depends on the lower  potential values, i.e. a higher density of 
negative charges at NP surface. Moreover, the presence of flexible HA chains on NP 
surface may help to improve NP steric stability and hydration. 
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Selected TEM micrographs of  P, PP and PPHA NPs are reported in figures 4.4, 4.5 and 
4.6, respectively.  
 
 
Figure 4.4: selected TEM micrographs of P NPs 
 
 
Figure 4.5: selected TEM micrographs of PP NPs 
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Figure 4.6: selected TEM (left) and AFM (right) micrographs PPHA NPs 
 
The images revealed discrete, spherical particles for all NP formulations. However, it must 
be underlined that PPHA NPs have a completely different appearance compared to P and 
PP NPs. Indeed, in the case of HA-containing NPs, there is, clearly, a sort of surface 
discontinuity, which cannot be noticed in both P and PP which, on the contrary, have a 
very smooth surface. These findings further corroborate the hypotheses of superficial HA 
arrangement/deposition. The shape and outer HA corona was also visible in AFM images 
(figure 4.6, right). 
The PP2HA30 formulation, hereafter named PPHA, has been selected for all the 
experiments reported in the following since it is optimized in terms of small size and 
dimensional stability. 
 
4.4.2 Theramal analyses  
The results of thermal analyses are shown in figure 4.7 and summarized in table 4.3.  
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Figure 4.7: DSC thermograms of PLGA powder (A) and poloxamer powder (B); P, PP and PPHA NPs first 
scan (C); P, PP and PPHA NPs, second scan (D). Results were obtained from at last three independent 
experiments 
 
 Tg, °C Tf, °C ΔHf, J/g c, °C ΔHc, J/g 
PLGA powder 47.7±0.1 - - - - 
Poloxamers - 54.2±0.1 140±3 36.3±0.2 127±3 
P NPs 44.0±0.5 - - - - 
PP NPs 43.3±0.3 54.3±0.2 28.1±9.4 27.8±4.8 23.3±9.2 
PPHA NPs 43.6±0.8 51.7±0.2 37.3±4.2 26.8±3.2 28.6±15.1 
Table 4.3: results of thermal analyses. The mean values and standard deviations were calculated from at last 
three independent experiments 
 
As it can be seen, the PLGA thermogram shows a glass Tg around 48 °C while, as for the 
poloxamers, crystallization and melting are shown at about 36 °C and 54 °C, respectively. 
As for HA powder, DSC traces showed no thermodynamic transition in the temperature 
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range here examined (data not shown). In the case of P NPs, the Tg is lower than that of the 
powder of PLGA (~ 44 °C instead of ~ 48 °C), therefore pointing at a plasticizing action of 
the poloxamers used as surfactants in the aqueous phase of the emulsion. The Tg values 
were found very similar also when the poloxamers have been blended in the organic phase 
of the emulsion (i.e. for PP and PPHA NPs), therefore indicating the same plasticizing 
effect of poloxamers also when they are in the bulk of NPs. Furthermore, as depicted in 
figure 4.7, when analyzing PP NPs, a broadening of poloxamer crystallization peak, along 
with a decrease of their crystallization heat (ΔHc) and temperature (Tc) has been observed. 
This suggests an amorphous interaction between the polymeric chains of PLGA and 
poloxamers when they are solubilized into the organic phase of the emulsion used to 
produce the NPs. In actual fact, as we have previously hypothesized, due to the 
amphiphilic nature of poloxamers, the hydrophobic PO segments preferentially self-orient 
towards the PLGA NP core, while the hydrophilic EO segments direct towards the aqueous 
phase [Mayol et al., 2015]. In the presence of HA in NP formulation, melting and 
crystallization do not significantly change compared to PP NPs, demonstrating that 
poloxamer crystallization is not further hampered. Moreover, it must be underlined that, in 
the first heating ramp, the Tg of PLGA is observable in NPs while, in the second scan 
(figure 4.7 D), after poloxamer melting, PLGA Tg and poloxamer crystallization peak are 
no longer visible. This may support the hypothesis that, in PPHA NPs, PLGA and HA do 
not interact since PLGA constitute NP bulk while HA is superficially exposed with the 
poloxamers acting as a bridge between the PLGA and HA. After poloxamer melting, this 
configuration is lost and a polymeric blend, with thermal properties different from the ones 
of the starting polymers, is formed. This hypothesis of polymer self-assembly into the NPs 
is also corroborated by the previously shown morphologic and  potential results.  
 
4.4.3 IRIN encapsulation efficiency, NPs yield and HA quantification 
PPHA drug entrapment efficiency was found to be 61.2 % (w/w), while for P NP it was 
58.8 % (w/w), as reported in table 4.4. Results of ELISA assay showed a loss of 34.3% 
w/w of HA in the supernatant (data not shown). 
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Forms Polymer:drug ratio 
Drug encapsulation 
efficiency (%) 
NP yield (%) 
P 10.5 ± 0.4 62.6 ± 2.5 65.9 ± 4.2 
PP 8.2 ± 0.5 64.9 ± 3.3 53.0 ± 7.8 
PPHA30 10.0 ± 0.5 62.7 ± 3.4 48.0 ± 6.8 
PPHA60 9.7 ± 0.3 64.1 ± 1.8 38.9 ± 10.0 
Table 4.4: polymer-to-drug ratio, drug encapsulation efficiency and NP yield. The mean values and standard 
deviations were calculated from at last three independent experiments 
 
4.4.4 In vitro release kinetic of IRIN 
Experimental in vitro release profiles of IRIN from P and PPHA NPs are reported in figure 
4.8.  
 
0
0.2
0.4
0.6
0.8
1
0 100 200 300 400
P NPs
PPHA30 NPs
R
el
ea
se
d
 IR
IN
 fr
a
ct
io
n
time, h  
Figure 4.8: in vitro IRIN release profiles from P and PPHA30 NPs 
 
The results demonstrated that IRIN is completely released in less than two weeks, with > 
85% of the loaded drug eluted within 7 days. In both formulations, a strong burst is 
evidenced. It can also be seen that IRIN release is slightly slower in the case of HA-
containing NPs. This can be probably ascribed to a slightly higher affinity of IRIN for the 
amphiphilic HA-containing NPs compared to simple P NPs.  
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4.4.5 In vitro cytotoxicity studies  
HS578T and L929 cell lines were employed to investigate the cytotoxicity of PP NP and 
PPHA30 NPs using alamar blue assay. The IRIN IC50 for L929 cells was found to be 51.7 
µM, while the IRIN IC50 for HS578T cells was 100.5 µM. The NP concentrations used in 
the experiments were chosen as those able to load IRIN at a dose equivalent to its IC50. 
Results from cell culture studies related to in vitro bioefficacy of IRIN-loaded PPHA30 
NPs and PP NPs are presented in figure 4.9.  
 
 
 
 
 
 
 
 
Figure 4.9: results of cytotoxicity assay. Percentage of viable L929 cells after 48 hours incubation (A) and of 
HS578T cells after 48 and 72 hours of incubation (B). Cell viability was calculated with respect to the non-
treated control cells. *P < 0.05 vs the respective unloaded NP 
 
As to L929 cells (figure 4.9 A) it is possible to observe unloaded NPs are not toxic. Indeed, 
the percentage of viability, compared to the control, for PP and PPHA30 is almost 100%. 
Differently, for both the IRIN-loaded particles, the percentage of viability is about 40%. 
This result indicates that PP and PPHA30 particles are able to inhibit the cells growth and 
that HA coating does not influence this ability. Also in the case of HS578T cells (figure 4.9 
B), the unloaded NPs are not cytotoxic. Interestingly, in the case of IRIN-loaded NPs, the 
behaviors of PPHA30 and PP NPs are different both at 48 and, in a significant way, at 72 
hours. In particular, the percentage of cell viability is about 60% and 45% after 48 hours 
for PP and PPHA30 NPs, respectively, therefore indicating that HA-coated NPs can inhibit 
cellular growth more effectively compared to PP NPs. A more evident result was obtained 
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at 72 hours, being the percentage of viable cells about 20% and 50% for PPHA30 and PP 
NPs, respectively. Taken all together, these results suggest that PPHA30 NPs can deliver 
more drugs into cancer cells and resulting in a stronger cell killing effect, probably due to 
the HA receptor-mediated endocytosis and therefore a better NP cellular uptake in CD44
+
 
cells. 
 
4.5 Conclusions  
In this study, a novel strategy to directed the self-assembly of tumor targeting HA moieties 
on IRIN-loaded PLGA NPs is proposed. This novel NP production method is easily up-
scalable, being a single step process. The NPs showed a spherical shape and a size ranging 
from 100 to 306 nm. Thermal analyses revealed that in the produced NP formulations 
PLGA, poloxamer and HA act as independent entities and not as a polymeric blend. These 
results, together with the results of  potential analyses, suggest a polymer self-
organization driven by a gradient of lipophilicity between the oil and water phases of the 
emulsion used to prepare the NPs. The HA cover enhances NP size stability over time due 
to an enhanced electrostatic repulsion of HA coated NPs and also to a higher degree of 
hydration and/or to a steric stability caused by the presence of flexible HA chains on NP 
surface. The amphiphilic nature of these NPs, characterized by an inner hydrophobic core 
and a hydrophilic shell, allowed to obtain a drug encapsulation efficiency of 61.2% w/w. 
The in vitro release profiles showed a sustained IRIN release up to 7-13 days. Cell 
cytotoxicity tests showed that PPHA30 NPs can deliver more drugs into cancer cells 
resulting in a stronger cell killing effect on CD44-overexpressing cells, probably due a 
positive effect of HA on NP internalization. 
 Taken all together, these results designate PPHA NPs as promising candidates for targeted 
drug delivery to solid tumors for a number of significant cancer types.  
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CHAPTER 5 
In vitro evaluation of tumor targeting ability of enoxaparin-coated self-
emulsifying drug delivery systems (SEDDS) for parenteral 
administration 
 
ABSTRACT 
Aim: To develop parenteral Enox-coated SEDDS for tumor targeting. Methods: Enox 
moieties have been chemically conjugated to palmitoyl chloride. Coated SEDDS were 
prepared by mixing the Enox-palmitoyl conjugate with uncoated SEDDS and characterized 
regarding size and  potential. Cell uptake studies were performed on human breast 
adenocarcinoma and on human epithelial colorectal adenocarcinoma cell lines. Results: 
Enox-coated SEDDS exhibited a size of 102 nm and a  potential of -11 mV. About 89% of 
loaded Enox-palmitoyl conjugate was found on SEDDS surface. Cell uptake of Enox-
coated SEDDS was found to increase on both cell lines, compared to uncoated SEDDS. 
Conclusions: Enox-coated SEDDS can be considered as a promising carrier for targeted 
administration of anticancer drugs. 
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5.1 Introduction  
Novel cancer therapies based on active targeting to malignant cells represent a promising 
approach to overcome the numerous and serious side effects being associated with 
conventional chemotherapeutic drugs. The active targeting is achieved by decorating drug 
delivery systems with specific ligands having high affinity toward surface-receptors and/or 
antigens over-expressed in tumor tissues [Bar-Zeev et al., 2017; Bhadra et al., 2002; Bi et 
al., 2016; Ding et al., 2012; Giarra et al., 2016; Kommareddy et al., 2005; Li et al., 2016; 
Torchilin, 2006]. In this context, several studies demonstrated that LMWH, obtained by 
chemical or enzymatic depolymerization of UFH, exhibit anticancer properties against 
different types of tumors [Castelli et al., 2004; Petit et al., 2000; Yang et al., 2015]. Their 
antitumor activity is related to their ability to bind various extracellular targets involved in 
the metastasis formation and over-expressed in many tumor tissues [Achour et al., 2016; 
Bouris et al., 2015; Chen et al., 2015]. Moreover, LMWH can also inhibit the activity of P- 
and L-selectins being involved in cell-cell interactions, and of fibroblast growth factor 
(FGF) as well as vascular endothelial growth factor (VEGF), involved in angiogenesis 
process [Casu et al., 2008; Gomes et al., 2015; Läubli and Borsig, 2010; Zhong et al., 
2015]. In particular, Enoxaparin (Enox) has attracted great attention as tumor-active 
targeting ligand, due to its high binding affinity towards fibrinogen-derived products and 
angiogenic growth factors, which are over-expressed in the stroma of some tumors but not 
in healthy tissues [Chung et al., 2010; Liang and Kiick, 2014; Nurunnabi et al., 2012; Ye 
et al., 2015].  
On the other hand, SEDDS are encountering a growing interest as drug delivery systems. 
They are based on a mixture of lipids, surfactants and co-solvents that, once in aqueous 
medium, under gentle agitation, spontaneously form transparent and kinetically stable 
nanoemulsions [Cherniakov et al., 2015; Khan et al., 2012; Kollipara and Gandhi, 2014]. 
Apart from their oral use, SEDDS have also attracted attention for the parenteral 
administration of hydrophobic drugs, particularly because of their physical stability, low 
costs of manufacturing and ease scale-up [Date and Nagarsenker, 2008a; Date and 
Nagarsenker, 2008b; Talegaonkar et al., 2008].  
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5.2 Aim of the work 
In this work, we investigated the possibility to develop Enox coated SEDDS as novel 
carriers for systemic administration and targeting tumors. Palmitoyl chloride was therefore 
covalently attached to Enox and the resulting conjugate (E-Pa) was incorporated into 
SEDDS. Then, the SEDDS were characterized in terms of size,  potential, protein 
adsorption, stability in serum and hemolytic activity. Finally, cellular uptake of E-Pa 
coated SEDDS was evaluated on two different cancer cell lines and compared with the 
uncoated SEDDS formulation. 
 
5.3 Materials and methods  
5.3.1 Materials 
Enox (average MW 4500 Da) was purchased from Sanofi-Aventis GmbH (Austria). 
Capmul
® 
PG8 (propylene glycol monocaprylate) was a gift from Abitec (USA); Peceol
TM
 
(glyceryl monooleate) and Labrafil® M 1944 (oleoyl polyoxyl-6 glycerides) were a gift 
from Gattefossé (France). Palmitoyl chloride (PC), Cremophor EL (polyoxyl-35 castor 
oil), propylene glycol (PG), Fe (III) chloride, L-cysteine ethyl ester hydrochloride, 
toluidine blue, sodium chloride (NaCl), triton X-100, fluorescein diacetate (FDA), sodium 
hydroxide (NaOH), tetrahydrofuran (THF), bovine serum albumin (BSA) and n-hexane 
were obtained from Sigma-Aldrich (Austria). L-Arginine from Alfa Aesar GmbH 
(Germany), hydroxylamine hydrochloride from Acros Organics (USA) and potassium 
hydroxide (KOH) from Gatt-Koller (Austria) were used. Fetal bovine serum (FBS), 
phosphate buffer saline (PBS), Minimum Essential Medium (MEM) and 
penicillin/streptomycin were purchased from Stricker (Austria). Opti-MEM and RPMI 
medium were obtained from Gibco (Austria). All solvents, chemicals and media were of 
analytical grade and used as received. 
 
5.3.2 Uncoated SEDDS preparation  
Uncoated SEDDS were prepared as previously described by Zupančič et al. [Zupančič et 
al., 2016] with some modifications. Briefly, 20% Peceol, 40% Cremophor EL, 30% 
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Labrafil-1944 and 10% PG were gently mixed by vortex and kept at room temperature 
until use.  
 
5.3.3 Synthesis of Enox-palmitoyl conjugate (E-Pa)  
The E-Pa conjugate was obtained through ester bond formation between a highly reactive 
acid halide and Enox hydroxyl groups; the reaction involves HCl release. Briefly, 500 µL 
of PC dissolved in tetrahydrofuran were added dropwise to 500 µL of Enox aqueous 
solution (500 µg/mL), at different molar ratios (E-Pa1:1; E-Pa1:50; E-Pa1:100; E-Pa1:150; E-
Pa1:200). The resultant solution was mixed on a vortexer for 2 minutes and then included on 
a thermo-mixer (Eppendorf), at 37 °C and 700 rpm for one hour. Afterwards, the 
temperature was set at 25 °C and the samples were shaken at 700 rpm overnight to allow 
the evaporation of the organic solvent. The obtained aqueous phase, containing the E-Pa 
conjugate, was centrifuged at 13000 rpm for 20 minutes (Minispin, Eppendorf) to remove 
the unreacted PC, lyophilized (Christ Gamma 1-16 LSC Freeze dryer) and stored at 4 °C 
until use. Bromophenol blue (0.03% w/v) was added to the resultant solution to test the 
progression of the reaction by measuring the pH of the different prepared conjugates.  
 
5.3.4 Size exclusion HPLC (SEC-HPLC) for E-Pa quantification 
The amount of unreacted Enox and of different E-Pa conjugates in the reaction mixture 
was quantified by SEC-HPLC following a method previously described by Matanović et 
al. [Matanović et al., 2015], but with some modifications. The Chromaster Hitachi HPLC-
systems was equipped with 5430 diode array detector, 5310 column oven, 5260 
autosampler and 5160 pump. Analyses were performed on a BioSep-SEC-S 2000 column 
(300 x 7.80 mm, 5 µm) at a detection wavelength of 215 nm using a mobile phase 
composed of 1 mg/mL L-arginine solution (pH arranged to 6.5 with 0.1 M HCl). The flow 
rate was 1 mL/min, the injection volume was 90 µL and the temperature was set at 40 °C. 
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5.3.5 Evaluation of the degree of Enox-OH substitution by iron (III)/hydroxylamine 
assay  
The degree of Enox-OH substitution was evaluated indirectly through iron 
(III)/hydroxylamine assay, a quantitative colorimetric method for carboxyl-ester 
determination previously described by Kakáč et al. [Kakáč and Vejdělek, 1976]. Briefly, 
250 µL of 15% (w/v) hydroxylamine hydrochloride solution and 10.5 M potassium 
hydroxide solution were added to 500 µL of about 1.2 mg/mL of sample solution in water 
and left to react for 15 min. Then, 750 µL of 3 M hydrochloric acid solution was added to 
the resultant mixture and the pH was adjusted to 1.1-1.5 with NaOH. Afterwards, 250 µL 
of 0.37 M iron (III) solution in 0.1 M hydrochloric acid and 125 µL of isopropyl alcohol 
were added to the sample solution and left to react for 10 min, thus obtaining a red to 
purple solution. The used reagents were kept at 4 °C until use. All steps were performed in 
ice bath at a temperature around 1±0.1 °C. The ester concentrations were evaluated by 
measuring the absorbance at λ=520 nm using a calibration curve of L-cysteine ethyl ester 
hydrochloride in the concentration range of 1.25- 20 mg/mL (r
2
=0.995).  
 
5.3.6 E-Pa coated SEDDS preparations and characterization 
The lyophilized E-Pa conjugates were dissolved in DMSO and added to the SEDDS 
formulation at a final concentration of 1 mg/g, respectively. The resultant emulsion was 
included on a thermo-mixer at 25 °C and 700 rpm overnight. Afterwards, the formulation 
was purified by dialysis membrane (cut-off 16000 Da) in water for 4 hours. The ζ-potential 
of the uncoated formulation and of the E-Pa coated SEDDS formulation was measured by 
emulsifying the pre-concentrate in water (1% w/v) (Malvern, UK). 
 
5.3.7 SEDDS stability studies 
The adsorption of proteins on SEDDS surface is a critical issue for their in vivo stability 
after intravenous injection. The interaction with serum proteins and the possibility of self-
aggregation were evaluated by monitoring the mean size and polydispersity index of the 
uncoated formulation (named 1) and of the corresponding E-Pa coated formulation (1+E-
Pa1:200, 1% w/v) in serum albumin (1% w/v in water) and in plasma (diluted 1:100 in 20 
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mM phosphate buffer, pH 7.4) up to 4 hours at 37 °C. ζ potential stability analyses were 
also performed in water up to 4 hours at 37 °C. 
 
5.3.8 Quantification of the amount of E-Pa1:200 on SEDDS surface by toluidine blue 
assay 
The amount of E-Pa1:200 conjugate on the SEDDS surface was evaluated indirectly by 
toluidine blue colorimetric assay exploiting the capability of toluidine blue to bind to the 
free sulfate groups of Enox [Han et al., 2006]. Briefly, during the 1+E-Pa1:200 purification 
process, aliquots of the external water phase, containing the E-Pa1:200 conjugate released 
from the SEDDS, were withdrawn at predetermined time points and kept at 4°C. 
Afterwards 300 µL of toluidine blue solutions (25 mg in 500 mL 0.01 M HCl, containing 
0.2% w/v NaCl) were added to 200 µL of each aliquot and left to react in a thermo-mixer 
at 25 °C and 700 rpm for 30 minutes. Then, 300 µL of n-hexane were added to the 
resultant solution, shortly mixed and the absorbance of the unreacted toluidine blue in the 
aqueous phase was measured at λ=631 nm (Microplate-reader, TECAN Infinite M200). 
The amount of E-Pa1:200 conjugate on the SEDDS surface was determined by subtracting 
the amount lost during the purification from the loaded one. The linearity of the response 
was assessed in the 7.8-125 µg/mL E-Pa1:200 concentration range (r
2
=0.996). 
 
5.3.9 In vitro hemolysis assay and sterility test 
The in vitro hemolysis assay is a fast and reliable test for evaluating the damage and lysis 
of erythrocytes cytoplasmic membrane. It was carried out with a method previously 
described by Mahmoud et al. [Mahmoud et al., 2014], but with some modifications. 
Briefly, human blood was diluted 1:10 with NaCl 0.9% (w/v) and then 0.2% (w/v) of 
uncoated and E-Pa1:200 coated formulations were added, mixed at 600 rpm for 30 s by 
vortex and incubated in a shaker bath at 37 °C for 4 hours. The negative control (0% 
hemolysis) was obtained by diluting 1:10 human blood in NaCl 0.9% (w/v), whereas the 
positive control (100% hemolysis) was prepared by adding 0.5% (v/v) of Triton-X in 
diluted 1:10 human blood with NaCl 0.9% (w/v). Afterwards, the samples were withdrawn, 
placed on ice for 2 minutes to quench erythrocyte lyses and centrifuged (3000 rpm for 5 
minutes) to separate the supernatant from the pellet, consisting of intact red blood cells. 
104 
 
The obtained supernatant was centrifuged another time (3000 rpm for 5 minutes) and the 
content of hemoglobin was measured at λ=540 nm. To verify the possibility to sterilize 
SEDDS by filtration, the formulations were diluted in NaCl (0.9% w/v) at a final 
concentration of 1% (w/v). The droplet mean diameter and polydispersity index were 
measured before and after filtration trough cellulose acetate filter (0.2 µm).  
 
5.3.10 Cell cultures 
Human breast adenocarcinoma MDA-MB-231 cell line, kindly donated by Professor Ira-
Ida Skvortsova (EXTRO-lab, Department for Therapeutic Radiology and Oncology, 
Medical University Innsbruck), was cultured as monolayer in culture flask using RPMI 
medium, supplemented with 10% (v/v) FBS, 2 mM L-glutamine and 
penicillin/streptomycin solution (100 units/0.1 mg/L). Human epithelial colorectal 
adenocarcinoma Caco-2 cell line, obtained from European Collection of Cell Culture 
(ECACC, Health Protection Agency, Porton Down, Salisbury, Wiltshire, UK) was cultured 
as monolayer in culture flask using MEM medium supplemented with 10% (v/v) heat 
inactivated FBS and penicillin/streptomycin solution (100 units/0.1 mg/L). Both cell 
cultures were maintained at 95% humidity and 37 °C in 5% CO2 atmosphere.  
 
5.3.11 In vitro toxicity assay 
The in vitro potential toxicity effect of the formulations 1 and 1+E-Pa1:200 were evaluated 
by resazurin assay using two different cell lines. Briefly approximately 1x10
5
 MDA-MB-
231 and 2x10
5
 Caco-2 cells/well were seeded to a 24-well plate and incubated with 500 µL 
of different SEDDS concentrations (0.5 w/v, 0.25 w/v, 0.1 w/v) in opti-MEM for 4 hours. 
Untreated cells were used as negative control. After 4 hours the formulations were 
removed and cells were washed twice with sterile PBS (pH=7.1) and incubated with 500 
µL of resazurin solution (44 µM) in White Medium for 2 hours. After incubation, the 
absorbance of the supernatant was measured by fluorometric assay (Microplate-reader, 
TECAN Infinite M200)  (λex=540 nm, λem= 590 nm). Results were calculated as follows:  
                                    Fluorescence of treated cells 
Cell viability (%) =                                                       x 100 
                                   Fluorescence of untreated cell 
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5.3.12 In vitro cellular uptake studies  
Fluorescent SEDDS were prepared by adding 20 µL of FDA solution (25 mg/mL in ACN) 
to 500 mg of formulations 1 and 1+E-Pa1:200. Approximately 1x10
5
 MDA-MB-231 and 
2x10
5
 Caco-2 cells/well were seeded to a 24-well plate. Afterwards, cells were incubated 
with 0.25 % (w/v) of formulations in opti-MEM. After 4 hours of incubation, cells were 
washed twice with prewarmed sterile PBS (pH=7.1), lysed with 5 M NaOH containing 1% 
w/v Triton-X and re-incubated for 30 min. The lysed cells without the removal of the 
formulations after 4 hours of incubations were used as positive control (100% uptake), 
whereas untreated cells were used as negative control (0% uptake). At the end of the 
incubation time all samples were transferred in 2 mL tubes, centrifuged (13000 rpm, 5 
min) and the intensity of fluorescence of the lysates were measured by fluorimeter 
(λex=485 nm, λem= 555 nm). Results were expressed through the equation: 
                         Fluorescence of lysate with removing formulation 
Uptake (%) =                                                                                     x 100 
                                    Fluorescence of positive control 
 
 
5.3.13 Statistical data analysis 
Statistical data analyses were performed using Student’s t-test for comparison of two 
paired groups, assuming p˂0.05, p<0.01 and p˂0.001 as levels of significance. All 
experiments were performed in triplicate and the results are reported as the means ±SD. 
 
5.4 Results and discussion 
5.4.1 Synthesis and characterization of E-Pa conjugate  
The E-Pa conjugate was obtained by covalently attaching palmitoyl chloride to the 
hydroxyl groups of Enox, through an ester bond formation as schematically represented in 
figure 5.1.  
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Figure 5.1: schematically representation of synthetic reaction and chemical structures of Enox, PC and E-Pa 
conjugate 
 
A simple acylation reaction in aqueous environment was carried out, thus not requiring the 
removal of any organic solvent [Kočevar et al., 2007; Kabanov et al., 1990]. This approach 
was considered advantageous especially for formulations that could be proposed for further 
clinical and industrial development. Acronyms and the molar ratios of the different 
components used for the preparations of conjugates are summarized in table 5.1. 
 
Conjugates 
Acronym 
Enox     
(mol) 
PC     
(mol) 
Degree of Enox-OH 
substitution (%) 
E-Pa1:1 1 1 0.000±0.61 
E-Pa1:50 1 50 45.26±3.70 
E-Pa1:100 1 100 62.10±2.32 
E-Pa1:150 1 150 70.54±1.15 
E-Pa1:200 1 200 84.38±2.13 
Table 5.1: acronyms, composition and degree of Enox-OH substitutions (%), measured by iron 
(III)/hydroxylamine assay, of the different E-Pa conjugates 
 
+ 
Enox PC 
E-Pa conjugate 
+ HCl 
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The acylation reaction produces one mole of HCl per mole of formed esters. The HCl 
release leads to a pH change in the solution, which was used to evaluate the progression of 
the reaction, by adding bromophenol blue at the final solution. As expected, when 
increasing PC content, the pH value shifted from ~ 5.3 (only Enox) to ~ 1.8 (E-PC1:200) 
(figure 5.2).  
 
 
Figure 5.2: pH evaluation of different conjugates after the addiction of bromophenol blue (0.03% w/v) at the 
solutions 
 
Then, SEC-HPLC analysis was performed to investigate the yield of the conjugation 
reaction. A single peak was found in Enox SEC-HPLC chromatogram at the retention time 
of 8.5 min, while no peaks were observed in the PC chromatogram. Differently, in the 
chromatograms of E-Pa1:50, E-Pa1:100 and E-Pa1:150 a second peak appeared at retention time 
of about 11.6 min, ascribable to the conjugate formation. In detail, the area of the peak 
attributed to the conjugate increased whit increasing PC concentration, while the area of 
the peak at 8.5 min decreased. In the chromatogram of E-Pa1:200 only the peak at retention 
time 11.6 min was observed, thus suggesting that using E/PC molar ratio of 1:200, 100% 
of the Enox was converted into E-Pa conjugate. Representative chromatograms of Enox 
and E-Pa1:200 conjugate are illustrated in figure 5.3 A. The concentration (expressed as % 
v/v) of the different E-Pa conjugates obtained as well as of the unreacted Enox, measured 
by integrating the area of the peaks acquired by SEC-HPLC chromatograms, are reported 
in figure 5.3 B. 
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In order to confirm the E-Pa conjugate formation and to evaluate the degree of Enox-OH 
substitution, iron (III)/hydroxylamine colorimetric assay was performed. The assay is 
based on the reaction between the ester groups with hydroxylamine to form a hydroxamic 
acid, which then reacts with ferric ion forming a spectrophotometrically visible chelate 
ferric hydroxamate complex. In this way, it was possible to determine the degree of Enox-
OH groups reacted with the acyl halide PC. Results shown in table 5.1 confirmed that the 
degree of Enox-OH substitution progressively increases with increasing amounts of PC 
being present at the coupling reaction, resulting in a maximum of 84.38% substitution for 
E-Pa1:200 conjugate. 
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Figure 5.3: representative SEC-HPLC chromatograms of Enox and E-Pa1:200 conjugate (A) and 
concentrations (% v/v) of E-Pa conjugates and unreacted Enox in function of Enox:PC molar ratios (B), 
measured by integrating the area of the peaks acquired by SEC-HPLC chromatograms 
B 
A 
109 
 
5.4.2 Preparation and characterization uncoated and E-Pa coated SEDDS  
Uncoated SEDDS formulation 1 was prepared and mixed with E-Pa conjugates prepared 
with different Enox/PC molar ratios, in order to obtain various E-Pa coated SEDDS as 
summarized in table 5.2. 
 
Formulation  d (nm) t=0 PI t=0 potential (mV)t=0  
1  91.09±1.05 0.255±0.02 -4.040±0.29  
1+ E-PC1:50  94.05±0.31 0.210±3.20 -6.735±0.54  
1+ E-PC1:100  92.30±1.20 0.190±2.10 -7.730±0.30  
1+ E-PC1:150  99.02±0.28 0.200±1.20 -7.285±0.23  
1+ E-PC1:200  102.3±0.04 0.234±0.04 -11.20±0.03  
Table 5.2: size, polydispersity index and potential of formulations, before and after addition of different 
conjugates E-Pa, in deionized water at 0 times 
 
Both uncoated and E-Pa coated SEDDS were diluted in water (final concentration 1% 
w/v), resulting in a clear nanoemulsion. Mean diameter, polydispersity index and ζ 
potential measurements of the prepared SEDDS are summarized in table 5.2. The mean 
diameter of the SEDDS droplets was influenced by the addition of conjugates to 
formulations, as well as by the type of E-Pa conjugate. On the other hand, SEDDS showed 
a polydispersity index ranging from 0.190 to 0.255, suggesting that even due to the 
inclusion of E-Pa conjugates, SEDDS remained homogeneous in size. Moreover, the E-Pa 
addition resulted in a decrease of ζ potential from -4 mV to -11 mV. This could be ascribed 
to the amphiphilic properties of the conjugate that could locate its hydrophobic fatty acid 
ester chain into the lipid core of nanoemulsions, while exposing the hydrophilic and 
negatively charged Enox on SEDDS surface. 
 
5.4.3 SEDDS stability studies 
The adsorption of proteins on the surface of nanocarriers is considered a crucial issue for 
their in vivo stability following administration. After injection, nanovectors are rapidly 
eliminated from the systemic circulation since they are able to recognize and adsorb serum 
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proteins on their surface [Leroux et al., 1995]. This could promote their fast aggregation 
rendering them easily recognizable for macrophages of endoplasmic reticulum (RES) and 
resulting in their subsequent elimination and liver accumulation, where they may cause 
side effects, and/or vessel occlusion [Lenaerts et al., 1984; Owens and Peppas, 2006]. 
Nanocarriers surface properties play therefore a key role in the opsonisation process since 
a more negative ζ potential can prevent aggregation through electrostatic stabilization. 
Table 5.2 shows a decrease of the ζ potential values obtained by adding E-Pa conjugates to 
the formulation. This can be reasonably ascribed to the negative charge of Enox, 
presumably present on the droplet surface. In line with this, the lowest ζ potential was 
observed in case of the conjugate with the highest content in PC, namely of E-Pa1:200, for 
which a more efficient intercalation between E-Pa fatty acid chains and the lipid phase of 
the droplets can be hypothesized. Therefore, it was considered for further studies. The 
mean diameter and the polydispersity index, before and after adding E-Pa1:200, were 
monitored in serum albumin and in human plasma at 37 °C. As it can be observed in tables 
5.3 and 5.4, the formulation was stable in presence of E-Pa1:200 conjugate up to 4 hours.  
 
Form 
BSA 37°C 
d(nm)t=0 PIt=0 d(nm)t=4h PIt=4h 
1 113.1±1.07 0.21±0.08 114.1±4.88 0.16±0.04 
1+E-Pa1:200 111.8±1.34 0.23±0.01 106.7±4.46 0.21±0.01 
Table 5.3: size stability and polydispersity index of formulations 1, with and without E-Pa1:200, in BSA (1% 
w/v) at 0 time and after 4 hours at 37 °C 
 
Form 
PLASMA 37°C 
d(nm)t=0 PIt=0 d(nm)t=4h PIt=4h 
1 108.3±8.41 0.23±0.01 111.8±1.81 0.24±0.05 
1+E-Pa1:200 103.4±4.31 0.20±0.01 110.1±3.11 0.24±0.02 
Table 5.4: size stability and polydispersity index of formulations 1, with and without E-Pa1:200, in plasma 
(1:100) at 0 time and after 4 hours at 37 °C 
 
The inclusion of the E-Pa conjugate did not significantly affect the SEDDS stability in 
BSA and in serum. As for size and polydispersity index, also the ζ potential values of both 
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E-Pa1:200 coated formulations resulted stable for 4 hours at 37 °C (data not shown). Based 
on these results, it might be assumed that the prepared SEDDS, independently on the 
presence of E-Pa, should be stable in the blood stream.  
 
5.4.4 Quantification of the amount of E-Pa1:200 on SEDDS surface by toluidine blue 
assay 
It has been reported that the amount of heparin on the surface of nano-devices significantly 
influence their in vivo performance [Han et al., 2006]. In this study, it was possible to 
reach a maximum of E-Pa conjugate concentration of 1 mg/g (E-Pa conjugate/SEDDS). 
When adding a concentration higher than 1 mg/g, increase in droplet size and instability of 
the dispersion were observed. The amount of E-Pa on SEDDS surface was indirectly 
evaluated by toluidine blue assay. Results showed a loss of 11% of E-Pa1:200 conjugate 
after 10 min from the preparation in the external water phase during the purification step. 
Afterwards, a plateau was reached suggesting no further release of conjugate up to 4 hours 
(figure 5.4).  
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Figure 5.4: amount (%) of E-Pa1:200 on 1+E-Pa1:200 coated SEDDS surface, evaluated by toluidine blue assay 
during the purification process, up to 4 hours 
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5.4.5 In vitro hemolysis assay and sterility test 
One of the key requirements for a preparation intended for parenteral administration is its 
hemocompatibility. The results of the hemolysis assay showed for both uncoated and E-Pa 
coated SEDDS a hemolysis lower than 2% generally regarded as non-toxic level (data not 
shown) [Salzano et al., 2016]. Furthermore, another key requirement for systemic 
administration is the possibility to sterilize the formulation. Thus, both 1 and 1+E-Pa1:200 
formulations were diluted in physiologic solution (NaCl 0.9% w/v) and filtrated using 0.22 
m cellulose acetate filters. The size as well as the polydispersity index of both 
formulations did not undergo a significantly change after filtration (table 5.5). These 
results indicated that it is possible to obtain a sterile formulation by filtration, thus 
avoiding the high-temperature autoclave sterilization procedure, which may result 
detrimental for the formulation [Khachane et al., 2015].   
 
Formulation 
d(nm) in  
NaCl (0.9% w/v) 
pre-filtration 
IP  
in NaCl (0.9% w/v)  
pre-filtration 
d(nm)                        
in NaCl (0.9% w/v) 
post-filtration 
IP                                                  
in NaCl (0.9% w/v) 
post-filtration 
1 92.79±10.2 0.23±0.01 96.23±5.06 0.20±0.03 
1+E-Pa1:200 111.8±1.34 0.23±0.01 106.7±4.46 0.21±0.01 
Table 5.5: size and polydisperisty index of formulations 1, with and without E-Pa1:200, in NaCl (0.9% w/v), 
pre- and post-filtration through cellulose acetate filter (0.2 µm) 
 
5.4.6 In vitro cell uptake studies  
Viability of MDA-MB-231 and Caco-2 cells in the presence of uncoated and E-Pa coated 
SEDDS was assessed via resazurin assay. Cells were incubated with 1 and 1+E-Pa1:200 
formulations at different concentrations. Any cytotoxicity was observed when testing both 
uncoated and E-Pa coated SEDDS in concentrations up to 0.25% (w/v) on both cell lines 
(data not shown). Cell uptake of uncoated and E-Pa coated SEDDS, loaded with 
fluorescein diacetate (FDA) was evaluated via cell uptake studies on both MDA-MB-231 
and Caco-2 cell lines by measuring fluorescence derived from hydrolytic cleavage of FDA 
with NaOH. The uptake of 1+E-Pa1:200 coated SEDDS was found to increase 1.36-fold and 
1.86-fold on MDA-MB-231 and Caco-2 cells, respectively, compared to uncoated 
formulation (figure 5.5 A and B).  
113 
 
 
0
1
2
3
U
p
t
a
k
e
 (
%
)
Formulations
1 1+E-Pa1:200
0
1
2
3
4
5
U
p
t
a
k
e
 (
%
)
Formulations
1 1+E-Pa1:200
 
Figure 5.5: uptake efficiency (%) of formulations 1 and 1+E-PC1:200 (0.25% w/v), after 4 hours of incubation 
upon MDA-MB-231 cells (A) and Caco-2 cells (B). Results are expressed as means of three independent 
experiments ± SD (** p < 0.01) 
 
It is well known that several components of the ECM, such as different cytokines and grow 
factors are over-expressed in different kind of tumors exhibiting binding domains for UFH 
and its derivatives [Salatin and Khosroushahi, 2017]. Based on these considerations the 
presence of sulfate motif of Enox seems to be crucial for the interactions between the ECM 
binding domains and Enox coated delivery systems. As previously described, the acylation 
reaction between Enox and PC, to form E-Pa conjugate leads to an ester bond formation 
between the fatty acid and the hydroxyl groups of Enox. In this way, it was possible to 
preserve the sulfate groups, as confirmed by toluidine blue assay and consequently the 
Enox binding activity. These interactions enhanced the internalization of the 1+E-Pa1:200 
coated SEDDS into cancer cells via an Enox endocytosis mediated process.  
 
5.5 Conclusions 
In the present study, sterically stabilized Enox coated SEDDS for tumor targeting were 
successfully prepared with an easily upscalable method. This was achieved by firstly 
 ** 
 ** 
A B 
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preparing an amphiphilic conjugate able to direct the spontaneous exposition of Enox 
moieties on SEDDS surface. The in vitro cell uptake studies showed that the decoration of 
SEDDS with Enox increases the internalization efficiency on both MDA-MB-231 and 
Caco-2 cells, when compared with uncoated formulation. According to these results Enox-
coated SEDDS can be considered as a promising carrier for targeted administration of 
anticancer drugs. 
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CHAPTER 6 
Summary and future perspectives  
 
Due to several limitations and side effects of conventional anticancer therapy, new 
strategies based on controlled drug delivery systems have been attracting a great deal of 
interest over the last years. In particular, polysaccharide-based systems possess peculiar 
favorable properties, such as biodegradability, biocompatibility, large availability as 
natural source, low cost manufacturing process and easiness of chemical functionalization 
due to the presence of multiple reactive groups in their structures. For these reasons, in the 
present thesis, different aspects of using polysaccharides in innovative formulations with 
potential application in tumors treatment have been studied. More in detail, two different 
strategies were envisaged.  
In the first strategy, different thermoresponsive gels based on methylcellulose or 
poloxamers, with or without the polysaccharide hyaluronic acid, were designed, loaded 
with the chemokine CXCL12 and their in vitro ability to act as metastasis trap were 
analyzed (chapter 2). The use of this fake metastatic niche to divert and capture CXCR4
+
 
circulating tumor cells resulted helpful in capturing these target cells and possibly 
reducing/inhibiting the formation of metastasis. This work is also presented in two research 
articles submitted for publication in international sceinfific journals [Giarra S, Ieranò C, 
Biondi M, Napolitano M, Campani V, Pacelli R, Scala S, De Rosa G, Mayol L. 
Engineering of thermoresponsive gels as a fake metastatic niche toward the capture of 
CXCR4
+
 circulating tumor cells. Carbohydr Polym: under revision; Ieranò C, D'Alterio C, 
Giarra S, Napolitano M, Santagata A, Barbieri A, Campani V, Luciano A, Arra L, 
Anniciello A.M., Botti G, Mayol L, De Rosa G, Pacelli R Scala S. In vivo capture of early 
metastatic cells through a CXCL12 loaded-dermal filler. Theranostics: submitted]. 
The second strategy concerned the use of polysaccharides both as structural and coating 
component for different types of nano-carriers. In particular, polyelectrolyte complexes co-
loaded with doxorubicin and zoledronic acid were prepared with the main aim to overcome 
multidrug resistance against doxorubicin resistant tumors (chapter 3). Chitosan was used as 
structural component of such complexes that were prepared with a simple and easily up-
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scalable method. The co-delivery of the two active molecules resulted in an enhanced 
doxorucin delivery in doxorubicin resistent cancer cells, thus providing a promising 
approach to overcome multidrug resistance. A research article is currently in prepraration 
collecting the results of this study [Giarra S, Zappavigna S, Mayol L, Leonetti C, Caraglia 
M, De Rosa G. Chitosan-based polyelecrolyte complexes for doxorubicin and zoledronic 
acid combined therapy to overcome multidrug resistance. In Preparation]. 
In chapter 4, a novel strategy to modify irinotecan-loaded poly lactic-co-glycolic acid 
nanoparticles with hyaluronic acid moieties for tumor targeting has been proposed. This 
preparation method, based on a self-assembling strategy, is easy to scale-up and consist on 
a single step process. Cell cytotoxicity tests showed that hyaluronic acid-coated 
nanoparticles can enhance drug delivery into CD44
+
 cancer cells, probably due to the 
hyaluronic acid-receptor endocytosis mediated process. The results of this study are 
described in three research articles published in international scientific journals, all 
belonging to Q1 class [Mayol L, Serri C, Menale C, Crispi S, Piccolo M.T., Mita L, Giarra 
S, Forte M, Saija A, Biondi M, Mita D.G. (2015). Curcumin loaded PLGA-poloxamer 
blend nanoparticles induce cell cycle arrest in mesothelioma cells. Eur J Pharm Biopharm, 
93:37-45; Giarra S, Serri C, Russo L, Zeppetelli S, De Rosa G, Borzacchiello A, Biondi M, 
Ambrosio L, Mayol L (2016). Spontaneous arrangement of a tumor targeting HA shell on 
irinotecan loaded PLGA NPs. Carbohydr Polim, 140: 400-407; Serri C, Argirò M, Piras L, 
Mita D.G., Saija A, Mita L, Forte M, Giarra S, Biondi M, Crispi S, Mayol L (2017). Nano-
precipitated curcumin loaded particles: effect of carrier size and drug complexation with 
(2-hydroxypropyl)-b-cyclodextrin on their biological performances. Int J Pharm, 520:21-
28]. 
In the chapter 5, sterically stabilized enoxaparin coated self-emulsifying drug delivery 
systems for tumor targeting were successfully prepared with an easily up-scalable method. 
The study demonstrated that the enoxaparin-coated self-emulsifying drug delivery systems 
are suitable to be administered by intravenous route. The in vitro cell uptake studies 
showed that the decoration of self-emulsifying drug delivery systems with enoxaparin 
increases the uptake both on human breast adenocarcinoma and on human epithelial 
colorectal adenocarcinoma cell lines, when compared with uncoated formulation. The 
results of this study are reported in one research article submitted for publication in an 
international scientific journal [Giarra S, Lupo N, Mayol L, De Rosa G, Bernkop-Schnürch 
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A. In vitro evaluation of tumor targeting ability of enoxaparin-coated self-emulsifying drug 
delivery systems for parenteral administration. Nanomedicine (Lond): submitted].  
All together, the results of this thesis support the use of polysaccharides-based polymeric 
systems for different applications in tumor treatment although further investigation is 
required in order to optimize, clarify and support the advantages of these formulations. 
More in detail, in the chapter 3, hyaluronic acid-coated polyelectrolyte complexes for 
CD44
+
 cells targeting were developed. Despite hyaluronic acid-coated polyelectrolyte 
complexes were able to increase the drugs cytotoxicity compared to free drugs, they were 
no more potent compared with uncoated polyelectrolyte complexes, also in MCF7 cell 
lines overexpressing CD44 receptor. In this context, it would be important to quantify the 
amount of targeting hyaluronic acid moieties on polyelectrolyte complexes, available for 
the interaction with CD44 receptor. Moreover, taking into account that in many cases 
MCF7 cells do not overexpress CD44 receptor, further in vitro studies on different CD44
+
 
cancer cells will be needed  to confirm their efficacy by means of validated in vitro assay, 
able to evaluate also the degree of CD44 expression. In the chapter 5, enoxaparin coated 
self-emulsifying drug delivery systems for tumor targeting were successfully prepared. The 
potential usefulness of self-emulsifying drug delivery systems is well known for oral 
administration of lipophilic drugs. In this work we demonstrated the potential application 
of self-emulsifying drug delivery systems through parenteral route of administration. 
Future perspectives in this field, include the use of suitable excipients for loading of drugs 
with antitumor activity, with particular attention on their solvent capacity, miscibility and 
chemical stability, in order to obtain multifunctional drug delivery systems.  
Despite the large number of research work dealing with polysaccharide drug delivery 
systems for tumor treatment, there is an imbalance between the number of scientific 
publications and the number of marketed products. This could be related to the fact that, 
unfortunately, little is known about their safety on patients. After administration into the 
body, the fate of these polymeric systems could be different from what is expected since 
they may accumulate into non-target tissues, such as liver, spleen and bone marrow with 
toxic effects. To this end, studies on in vitro/in vivo tumor models are needed for 
evaluating their absorption, distribution, metabolism and excretion (ADME) after their 
administration into the body. Moreover, in silico modeling approaches able to mimic the 
interactions between drug delivery systems and the surface of living systems, will be 
needed for predicting their toxicity in human body. 
